{"idB": "908259_14_item1_p86_s0", "idA": "908259_13_item1_p106_s0", "sentA": "We expect that, if any of our products gain regulatory approval for sale, they will compete primarily on the basis of product efficacy, safety, patient convenience, reliability, price and patent protection.", "sentB": "Expedited Review and Approval The FDA has various programs, including Fast Track, priority review, and accelerated approval, which are intended to expedite or simplify the process for reviewing drugs, and/or provide for approval on the basis of surrogate endpoints.", "type": 1, "words": ["<tag1>", "We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection.", "<tag2>", "Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "and", "accelerated", "approval,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints.", "<tag3>"], "wordsA": ["We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection."], "wordsB": ["Expedited", "Review", "and", "Approval", "The", "FDA", "has", "various", "programs,", "including", "Fast", "Track,", "priority", "review,", "and", "accelerated", "approval,", "which", "are", "intended", "to", "expedite", "or", "simplify", "the", "process", "for", "reviewing", "drugs,", "and/or", "provide", "for", "approval", "on", "the", "basis", "of", "surrogate", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p8_s9", "idA": "908259_13_item1_p10_s0", "sentA": "Seven years of marketing exclusivity after the approval of the drug in the US and 10 years of exclusivity in the EU.", "sentB": "The original purpose of the analysis was to consider early study closure to limit patient exposure in the event that the experimental regimen was deemed futile (i.e., unlikely to be declared more effective than the reference regimen at the end of the study).", "type": 1, "words": ["<tag1>", "Seven", "years", "of", "marketing", "exclusivity", "after", "the", "approval", "of", "the", "drug", "in", "the", "US", "and", "10", "years", "of", "exclusivity", "in", "the", "EU.", "<tag2>", "The", "original", "purpose", "of", "the", "analysis", "was", "to", "consider", "early", "study", "closure", "to", "limit", "patient", "exposure", "in", "the", "event", "that", "the", "experimental", "regimen", "was", "deemed", "futile", "(i.e.,", "unlikely", "to", "be", "declared", "more", "effective", "than", "the", "reference", "regimen", "at", "the", "end", "of", "the", "study).", "<tag3>"], "wordsA": ["Seven", "years", "of", "marketing", "exclusivity", "after", "the", "approval", "of", "the", "drug", "in", "the", "US", "and", "10", "years", "of", "exclusivity", "in", "the", "EU."], "wordsB": ["The", "original", "purpose", "of", "the", "analysis", "was", "to", "consider", "early", "study", "closure", "to", "limit", "patient", "exposure", "in", "the", "event", "that", "the", "experimental", "regimen", "was", "deemed", "futile", "(i.e.,", "unlikely", "to", "be", "declared", "more", "effective", "than", "the", "reference", "regimen", "at", "the", "end", "of", "the", "study)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p29_s2", "idA": "908259_13_item1_p21_s1", "sentA": "The investigators observed disease stabilization in 9 of 14 treated patients, and a partial response lasting over one year in one patient with ovarian cancer, based on CA125 tumor marker levels.", "sentB": "Among the first 13 patients treated at the two lowest dose levels, two patients have shown stable disease, one patient had a partial remission and one patient achieved a complete bone marrow response.", "type": 1, "words": ["<tag1>", "The", "investigators", "observed", "disease", "stabilization", "in", "9", "of", "14", "treated", "patients,", "and", "a", "partial", "response", "lasting", "over", "one", "year", "in", "one", "patient", "with", "ovarian", "cancer,", "based", "on", "CA125", "tumor", "marker", "levels.", "<tag2>", "Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "have", "shown", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response.", "<tag3>"], "wordsA": ["The", "investigators", "observed", "disease", "stabilization", "in", "9", "of", "14", "treated", "patients,", "and", "a", "partial", "response", "lasting", "over", "one", "year", "in", "one", "patient", "with", "ovarian", "cancer,", "based", "on", "CA125", "tumor", "marker", "levels."], "wordsB": ["Among", "the", "first", "13", "patients", "treated", "at", "the", "two", "lowest", "dose", "levels,", "two", "patients", "have", "shown", "stable", "disease,", "one", "patient", "had", "a", "partial", "remission", "and", "one", "patient", "achieved", "a", "complete", "bone", "marrow", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p14_s0", "idA": "908259_13_item1_p23_s3", "sentA": "Due to the aggressive nature of the disease, fewer than 10% of patients are expected to survive one year from diagnosis.", "sentB": "Anaplastic Thyroid Cancer, or ATC Anaplastic thyroid cancer (ATC) is a rare, but particularly aggressive form of thyroid cancer that is resistant to mainstream cancer therapies and that has a particularly grim prognosis, with a median survival from diagnosis of three to four months and a one-year survival rate of less than 10%.", "type": 1, "words": ["<tag1>", "Due", "to", "the", "aggressive", "nature", "of", "the", "disease,", "fewer", "than", "10%", "of", "patients", "are", "expected", "to", "survive", "one", "year", "from", "diagnosis.", "<tag2>", "Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "Anaplastic", "thyroid", "cancer", "(ATC)", "is", "a", "rare,", "but", "particularly", "aggressive", "form", "of", "thyroid", "cancer", "that", "is", "resistant", "to", "mainstream", "cancer", "therapies", "and", "that", "has", "a", "particularly", "grim", "prognosis,", "with", "a", "median", "survival", "from", "diagnosis", "of", "three", "to", "four", "months", "and", "a", "one-year", "survival", "rate", "of", "less", "than", "10%.", "<tag3>"], "wordsA": ["Due", "to", "the", "aggressive", "nature", "of", "the", "disease,", "fewer", "than", "10%", "of", "patients", "are", "expected", "to", "survive", "one", "year", "from", "diagnosis."], "wordsB": ["Anaplastic", "Thyroid", "Cancer,", "or", "ATC", "Anaplastic", "thyroid", "cancer", "(ATC)", "is", "a", "rare,", "but", "particularly", "aggressive", "form", "of", "thyroid", "cancer", "that", "is", "resistant", "to", "mainstream", "cancer", "therapies", "and", "that", "has", "a", "particularly", "grim", "prognosis,", "with", "a", "median", "survival", "from", "diagnosis", "of", "three", "to", "four", "months", "and", "a", "one-year", "survival", "rate", "of", "less", "than", "10%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p15_s6", "idA": "908259_13_item1_p25_s0", "sentA": "In September 2012, we reached agreement with the U.S. Food and Drug Administration, or FDA, regarding a special protocol assessment, or SPA, for a pivotal Phase 3 clinical trial of ZYBRESTAT in ATC, which we refer to as the FACT 2 trial, and which would require enrolling 300 patients with ATC.", "sentB": "For additional details, please refer to Collaborative Research and Development Arrangements.", "type": 1, "words": ["<tag1>", "In", "September", "2012,", "we", "reached", "agreement", "with", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "regarding", "a", "special", "protocol", "assessment,", "or", "SPA,", "for", "a", "pivotal", "Phase", "3", "clinical", "trial", "of", "ZYBRESTAT", "in", "ATC,", "which", "we", "refer", "to", "as", "the", "FACT", "2", "trial,", "and", "which", "would", "require", "enrolling", "300", "patients", "with", "ATC.", "<tag2>", "For", "additional", "details,", "please", "refer", "to", "Collaborative", "Research", "and", "Development", "Arrangements.", "<tag3>"], "wordsA": ["In", "September", "2012,", "we", "reached", "agreement", "with", "the", "U.S.", "Food", "and", "Drug", "Administration,", "or", "FDA,", "regarding", "a", "special", "protocol", "assessment,", "or", "SPA,", "for", "a", "pivotal", "Phase", "3", "clinical", "trial", "of", "ZYBRESTAT", "in", "ATC,", "which", "we", "refer", "to", "as", "the", "FACT", "2", "trial,", "and", "which", "would", "require", "enrolling", "300", "patients", "with", "ATC."], "wordsB": ["For", "additional", "details,", "please", "refer", "to", "Collaborative", "Research", "and", "Development", "Arrangements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s6", "idA": "908259_13_item1_p28_s0", "sentA": "Background in ATC In earlier Phase 1 studies of ZYBRESTAT in ATC, clinical investigators observed several objective responses in treatment with ZYBRESTAT, including a complete response lasting more than 13 years, in patients with ATC.", "sentB": "We enhanced this intellectual property with data collected from various preclinical studies of ZYBRESTAT , some of which are ongoing.", "type": 1, "words": ["<tag1>", "Background", "in", "ATC", "In", "earlier", "Phase", "1", "studies", "of", "ZYBRESTAT", "in", "ATC,", "clinical", "investigators", "observed", "several", "objective", "responses", "in", "treatment", "with", "ZYBRESTAT,", "including", "a", "complete", "response", "lasting", "more", "than", "13", "years,", "in", "patients", "with", "ATC.", "<tag2>", "We", "enhanced", "this", "intellectual", "property", "with", "data", "collected", "from", "various", "preclinical", "studies", "of", "ZYBRESTAT", ",", "some", "of", "which", "are", "ongoing.", "<tag3>"], "wordsA": ["Background", "in", "ATC", "In", "earlier", "Phase", "1", "studies", "of", "ZYBRESTAT", "in", "ATC,", "clinical", "investigators", "observed", "several", "objective", "responses", "in", "treatment", "with", "ZYBRESTAT,", "including", "a", "complete", "response", "lasting", "more", "than", "13", "years,", "in", "patients", "with", "ATC."], "wordsB": ["We", "enhanced", "this", "intellectual", "property", "with", "data", "collected", "from", "various", "preclinical", "studies", "of", "ZYBRESTAT", ",", "some", "of", "which", "are", "ongoing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p0_s1", "idA": "908259_13_item1_p33_s0", "sentA": "As in other studies, ZYBRESTAT appeared to be well tolerated.", "sentB": "We are pursuing what we believe to be a cost-efficient, risk-mitigated development strategy.", "type": 1, "words": ["<tag1>", "As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated.", "<tag2>", "We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy.", "<tag3>"], "wordsA": ["As", "in", "other", "studies,", "ZYBRESTAT", "appeared", "to", "be", "well", "tolerated."], "wordsB": ["We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s2", "idA": "908259_13_item1_p39_s2", "sentA": "New patients are continuing to be enrolled in this study.", "sentB": "We may collaborate with clinical investigators from two U.K.-based non-profit research organizations, the Christie National Health Service (NHS) Foundation Trust and the Hillingdon Hospital NHS Trust and with GlaxoSmithKline in the implementation of this study.", "type": 1, "words": ["<tag1>", "New", "patients", "are", "continuing", "to", "be", "enrolled", "in", "this", "study.", "<tag2>", "We", "may", "collaborate", "with", "clinical", "investigators", "from", "two", "U.K.-based", "non-profit", "research", "organizations,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust", "and", "the", "Hillingdon", "Hospital", "NHS", "Trust", "and", "with", "GlaxoSmithKline", "in", "the", "implementation", "of", "this", "study.", "<tag3>"], "wordsA": ["New", "patients", "are", "continuing", "to", "be", "enrolled", "in", "this", "study."], "wordsB": ["We", "may", "collaborate", "with", "clinical", "investigators", "from", "two", "U.K.-based", "non-profit", "research", "organizations,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust", "and", "the", "Hillingdon", "Hospital", "NHS", "Trust", "and", "with", "GlaxoSmithKline", "in", "the", "implementation", "of", "this", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p18_s1", "idA": "908259_13_item1_p40_s3", "sentA": "Partial responses were observed in two patients with epithelial ovarian cancer and stable disease was observed in 9 patients.", "sentB": "These symptoms occur secondary to gastrointestinal neuroendocrine tumors (GI-NETs) in approximately 5% of patients.", "type": 1, "words": ["<tag1>", "Partial", "responses", "were", "observed", "in", "two", "patients", "with", "epithelial", "ovarian", "cancer", "and", "stable", "disease", "was", "observed", "in", "9", "patients.", "<tag2>", "These", "symptoms", "occur", "secondary", "to", "gastrointestinal", "neuroendocrine", "tumors", "(GI-NETs)", "in", "approximately", "5%", "of", "patients.", "<tag3>"], "wordsA": ["Partial", "responses", "were", "observed", "in", "two", "patients", "with", "epithelial", "ovarian", "cancer", "and", "stable", "disease", "was", "observed", "in", "9", "patients."], "wordsB": ["These", "symptoms", "occur", "secondary", "to", "gastrointestinal", "neuroendocrine", "tumors", "(GI-NETs)", "in", "approximately", "5%", "of", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p10_s5", "idA": "908259_13_item1_p40_s7", "sentA": "This study confirmed the recommended dose established in the first Phase 1 study.", "sentB": "The study may enroll approximately 120 patients at sites in the U.K.", "type": 1, "words": ["<tag1>", "This", "study", "confirmed", "the", "recommended", "dose", "established", "in", "the", "first", "Phase", "1", "study.", "<tag2>", "The", "study", "may", "enroll", "approximately", "120", "patients", "at", "sites", "in", "the", "U.K.", "<tag3>"], "wordsA": ["This", "study", "confirmed", "the", "recommended", "dose", "established", "in", "the", "first", "Phase", "1", "study."], "wordsB": ["The", "study", "may", "enroll", "approximately", "120", "patients", "at", "sites", "in", "the", "U.K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p21_s0", "idA": "908259_13_item1_p40_s7", "sentA": "This study confirmed the recommended dose established in the first Phase 1 study.", "sentB": "PNETs are highly vascularized tumors which originate in the pancreas.", "type": 1, "words": ["<tag1>", "This", "study", "confirmed", "the", "recommended", "dose", "established", "in", "the", "first", "Phase", "1", "study.", "<tag2>", "PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas.", "<tag3>"], "wordsA": ["This", "study", "confirmed", "the", "recommended", "dose", "established", "in", "the", "first", "Phase", "1", "study."], "wordsB": ["PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p22_s3", "idA": "908259_13_item1_p42_s0", "sentA": "Background in Ophthalmology In December 2010, we completed a randomized, double-masked, placebo-controlled Phase 2 proof-of-mechanism trial, which we refer to as the FAVOR trial, with a single dose of intravenously-administered ZYBRESTAT in patients with polypoidal choroidal vasculopathy, or PCV, a form of choroidal neovascularization, a condition where new blood vessels form in the choroid, a part of the eye, and which can lead to vision loss and, ultimately, blindness.", "sentB": "Treatment with ZYBRESTAT in this animal model resulted in a significant and sustained decrease in circulating insulin of more than 90% over four weeks following a single dose of ZYBRESTAT and was accompanied by a significantly reduced tumor size of greater than 80% in the treated group compared to the placebo treated group.", "type": 1, "words": ["<tag1>", "Background", "in", "Ophthalmology", "In", "December", "2010,", "we", "completed", "a", "randomized,", "double-masked,", "placebo-controlled", "Phase", "2", "proof-of-mechanism", "trial,", "which", "we", "refer", "to", "as", "the", "FAVOR", "trial,", "with", "a", "single", "dose", "of", "intravenously-administered", "ZYBRESTAT", "in", "patients", "with", "polypoidal", "choroidal", "vasculopathy,", "or", "PCV,", "a", "form", "of", "choroidal", "neovascularization,", "a", "condition", "where", "new", "blood", "vessels", "form", "in", "the", "choroid,", "a", "part", "of", "the", "eye,", "and", "which", "can", "lead", "to", "vision", "loss", "and,", "ultimately,", "blindness.", "<tag2>", "Treatment", "with", "ZYBRESTAT", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "following", "a", "single", "dose", "of", "ZYBRESTAT", "and", "was", "accompanied", "by", "a", "significantly", "reduced", "tumor", "size", "of", "greater", "than", "80%", "in", "the", "treated", "group", "compared", "to", "the", "placebo", "treated", "group.", "<tag3>"], "wordsA": ["Background", "in", "Ophthalmology", "In", "December", "2010,", "we", "completed", "a", "randomized,", "double-masked,", "placebo-controlled", "Phase", "2", "proof-of-mechanism", "trial,", "which", "we", "refer", "to", "as", "the", "FAVOR", "trial,", "with", "a", "single", "dose", "of", "intravenously-administered", "ZYBRESTAT", "in", "patients", "with", "polypoidal", "choroidal", "vasculopathy,", "or", "PCV,", "a", "form", "of", "choroidal", "neovascularization,", "a", "condition", "where", "new", "blood", "vessels", "form", "in", "the", "choroid,", "a", "part", "of", "the", "eye,", "and", "which", "can", "lead", "to", "vision", "loss", "and,", "ultimately,", "blindness."], "wordsB": ["Treatment", "with", "ZYBRESTAT", "in", "this", "animal", "model", "resulted", "in", "a", "significant", "and", "sustained", "decrease", "in", "circulating", "insulin", "of", "more", "than", "90%", "over", "four", "weeks", "following", "a", "single", "dose", "of", "ZYBRESTAT", "and", "was", "accompanied", "by", "a", "significantly", "reduced", "tumor", "size", "of", "greater", "than", "80%", "in", "the", "treated", "group", "compared", "to", "the", "placebo", "treated", "group."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p3_s1", "idA": "908259_13_item1_p49_s8", "sentA": "We believe the potential ability to synergistically combine VDA drugs with anti-angiogenic therapeutics affords it a wide range of future development and commercialization options with our VDA drug candidates, including tumor types and treatment settings where anti-angiogenic drugs are commonly utilized, as well as those where anti-angiogenic agents are either poorly tolerated, ineffective, no longer effective, or not commonly utilized.", "sentB": "Many patients eventually become resistant to platinum-based therapies, and new agents are needed.", "type": 1, "words": ["<tag1>", "We", "believe", "the", "potential", "ability", "to", "synergistically", "combine", "VDA", "drugs", "with", "anti-angiogenic", "therapeutics", "affords", "it", "a", "wide", "range", "of", "future", "development", "and", "commercialization", "options", "with", "our", "VDA", "drug", "candidates,", "including", "tumor", "types", "and", "treatment", "settings", "where", "anti-angiogenic", "drugs", "are", "commonly", "utilized,", "as", "well", "as", "those", "where", "anti-angiogenic", "agents", "are", "either", "poorly", "tolerated,", "ineffective,", "no", "longer", "effective,", "or", "not", "commonly", "utilized.", "<tag2>", "Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "agents", "are", "needed.", "<tag3>"], "wordsA": ["We", "believe", "the", "potential", "ability", "to", "synergistically", "combine", "VDA", "drugs", "with", "anti-angiogenic", "therapeutics", "affords", "it", "a", "wide", "range", "of", "future", "development", "and", "commercialization", "options", "with", "our", "VDA", "drug", "candidates,", "including", "tumor", "types", "and", "treatment", "settings", "where", "anti-angiogenic", "drugs", "are", "commonly", "utilized,", "as", "well", "as", "those", "where", "anti-angiogenic", "agents", "are", "either", "poorly", "tolerated,", "ineffective,", "no", "longer", "effective,", "or", "not", "commonly", "utilized."], "wordsB": ["Many", "patients", "eventually", "become", "resistant", "to", "platinum-based", "therapies,", "and", "new", "agents", "are", "needed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_14_item1_p2_s2", "idA": "908259_13_item1_p89_s0", "sentA": "Orphan Drug Designation Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug.", "sentB": "In fact, more than 60% of women diagnosed with ovarian cancer are in stage III or IV, making it difficult to treat and often fatal, with a five-year survival rate of 47% a rate which is largely unchanged since the 1990s.", "type": 1, "words": ["<tag1>", "Orphan", "Drug", "Designation", "Under", "the", "Orphan", "Drug", "Act,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "a", "drug", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States,", "or", "more", "than", "200,000", "individuals", "in", "the", "United", "States", "and", "for", "which", "there", "is", "no", "reasonable", "expectation", "that", "the", "cost", "of", "developing", "and", "making", "available", "in", "the", "United", "States", "a", "drug", "for", "this", "type", "of", "disease", "or", "condition", "will", "be", "recovered", "from", "sales", "in", "the", "United", "States", "for", "that", "drug.", "<tag2>", "In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag3>"], "wordsA": ["Orphan", "Drug", "Designation", "Under", "the", "Orphan", "Drug", "Act,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "a", "drug", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "United", "States,", "or", "more", "than", "200,000", "individuals", "in", "the", "United", "States", "and", "for", "which", "there", "is", "no", "reasonable", "expectation", "that", "the", "cost", "of", "developing", "and", "making", "available", "in", "the", "United", "States", "a", "drug", "for", "this", "type", "of", "disease", "or", "condition", "will", "be", "recovered", "from", "sales", "in", "the", "United", "States", "for", "that", "drug."], "wordsB": ["In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s12", "idA": "908259_14_item1_p0_s2", "sentA": "In the United States, we are pursuing collaborations with established pharmaceutical companies with products whose efficacy we believe can be enhanced by the addition of our lead product candidate, ZYBRESTAT , and with non-profit research organizations such as the Gynecologic Oncology Group, or GOG, an organization dedicated to clinical research in the field of gynecologic cancer, for the treatment of advanced ovarian cancer.", "sentB": "In the small subgroup of platinum-resistant patients, the addition of fosbretabulin to AVASTIN (bevacizumab) treatment increased ORR to 40.0 percent (n=10) compared to 12.5 percent (n=8) for AVASTIN (bevacizumab) alone.", "type": 1, "words": ["<tag1>", "In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer.", "<tag2>", "In", "the", "small", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "treatment", "increased", "ORR", "to", "40.0", "percent", "(n=10)", "compared", "to", "12.5", "percent", "(n=8)", "for", "AVASTIN", "(bevacizumab)", "alone.", "<tag3>"], "wordsA": ["In", "the", "United", "States,", "we", "are", "pursuing", "collaborations", "with", "established", "pharmaceutical", "companies", "with", "products", "whose", "efficacy", "we", "believe", "can", "be", "enhanced", "by", "the", "addition", "of", "our", "lead", "product", "candidate,", "ZYBRESTAT", ",", "and", "with", "non-profit", "research", "organizations", "such", "as", "the", "Gynecologic", "Oncology", "Group,", "or", "GOG,", "an", "organization", "dedicated", "to", "clinical", "research", "in", "the", "field", "of", "gynecologic", "cancer,", "for", "the", "treatment", "of", "advanced", "ovarian", "cancer."], "wordsB": ["In", "the", "small", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "treatment", "increased", "ORR", "to", "40.0", "percent", "(n=10)", "compared", "to", "12.5", "percent", "(n=8)", "for", "AVASTIN", "(bevacizumab)", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p3_s1", "idA": "908259_14_item1_p0_s4", "sentA": "To date, we have observed ZYBRESTAT to be well tolerated in over 400 patients and to have clinical activity in a variety of indications including ovarian cancer and ATC.", "sentB": "Patients are said to have platinum-resistant disease if the disease worsens within six months of completing platinum-based chemotherapy.", "type": 1, "words": ["<tag1>", "To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC.", "<tag2>", "Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "worsens", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy.", "<tag3>"], "wordsA": ["To", "date,", "we", "have", "observed", "ZYBRESTAT", "to", "be", "well", "tolerated", "in", "over", "400", "patients", "and", "to", "have", "clinical", "activity", "in", "a", "variety", "of", "indications", "including", "ovarian", "cancer", "and", "ATC."], "wordsB": ["Patients", "are", "said", "to", "have", "platinum-resistant", "disease", "if", "the", "disease", "worsens", "within", "six", "months", "of", "completing", "platinum-based", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p13_s0", "idA": "908259_14_item1_p0_s5", "sentA": "We have been granted orphan drug designation for ovarian cancer and ATC in the United States and the European Union.", "sentB": "The incidence of neuroendocrine tumors, or NETs, in 2004 in the US was approximately 5 per 100,000 people, indicating 14,000 new cases per year, and the incidence is increasing.", "type": 1, "words": ["<tag1>", "We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union.", "<tag2>", "The", "incidence", "of", "neuroendocrine", "tumors,", "or", "NETs,", "in", "2004", "in", "the", "US", "was", "approximately", "5", "per", "100,000", "people,", "indicating", "14,000", "new", "cases", "per", "year,", "and", "the", "incidence", "is", "increasing.", "<tag3>"], "wordsA": ["We", "have", "been", "granted", "orphan", "drug", "designation", "for", "ovarian", "cancer", "and", "ATC", "in", "the", "United", "States", "and", "the", "European", "Union."], "wordsB": ["The", "incidence", "of", "neuroendocrine", "tumors,", "or", "NETs,", "in", "2004", "in", "the", "US", "was", "approximately", "5", "per", "100,000", "people,", "indicating", "14,000", "new", "cases", "per", "year,", "and", "the", "incidence", "is", "increasing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s7", "idA": "908259_14_item1_p10_s10", "sentA": "We also remain interested in a conducting a randomized, two-arm Phase 2 clinical trial, comparing weekly dosing of TAXOL (paclitaxel) with weekly TAXOL (paclitaxel) plus ZYBRESTAT in patients with relapsed ovarian cancer.", "sentB": "Patients who participate in this trial are eligible to enroll in a rollover clinical trial which is designed to treat patients for one year after they complete the Phase 2 clinical trial if they have responded to our drug.", "type": 1, "words": ["<tag1>", "We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer.", "<tag2>", "Patients", "who", "participate", "in", "this", "trial", "are", "eligible", "to", "enroll", "in", "a", "rollover", "clinical", "trial", "which", "is", "designed", "to", "treat", "patients", "for", "one", "year", "after", "they", "complete", "the", "Phase", "2", "clinical", "trial", "if", "they", "have", "responded", "to", "our", "drug.", "<tag3>"], "wordsA": ["We", "also", "remain", "interested", "in", "a", "conducting", "a", "randomized,", "two-arm", "Phase", "2", "clinical", "trial,", "comparing", "weekly", "dosing", "of", "TAXOL", "(paclitaxel)", "with", "weekly", "TAXOL", "(paclitaxel)", "plus", "ZYBRESTAT", "in", "patients", "with", "relapsed", "ovarian", "cancer."], "wordsB": ["Patients", "who", "participate", "in", "this", "trial", "are", "eligible", "to", "enroll", "in", "a", "rollover", "clinical", "trial", "which", "is", "designed", "to", "treat", "patients", "for", "one", "year", "after", "they", "complete", "the", "Phase", "2", "clinical", "trial", "if", "they", "have", "responded", "to", "our", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p9_s3", "idA": "908259_14_item1_p10_s8", "sentA": "As in the combination therapy trial of ZYBRESTAT with AVASTIN (bevacizumab), which is sponsored and substantially funded by the National Cancer Institute, we believe that the potential collaboration among us, the Christie National Health Service (NHS) Foundation Trust, the Hillingdon Hospital NHS Trust, and GlaxoSmithKline, under the sponsorship and primary funding of our U.K. based collaborators, would help offset costs associated with this trial.", "sentB": "However, we believe that the OS data currently available is not sufficiently mature to yield any definitive conclusions.", "type": 1, "words": ["<tag1>", "As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial.", "<tag2>", "However,", "we", "believe", "that", "the", "OS", "data", "currently", "available", "is", "not", "sufficiently", "mature", "to", "yield", "any", "definitive", "conclusions.", "<tag3>"], "wordsA": ["As", "in", "the", "combination", "therapy", "trial", "of", "ZYBRESTAT", "with", "AVASTIN", "(bevacizumab),", "which", "is", "sponsored", "and", "substantially", "funded", "by", "the", "National", "Cancer", "Institute,", "we", "believe", "that", "the", "potential", "collaboration", "among", "us,", "the", "Christie", "National", "Health", "Service", "(NHS)", "Foundation", "Trust,", "the", "Hillingdon", "Hospital", "NHS", "Trust,", "and", "GlaxoSmithKline,", "under", "the", "sponsorship", "and", "primary", "funding", "of", "our", "U.K.", "based", "collaborators,", "would", "help", "offset", "costs", "associated", "with", "this", "trial."], "wordsB": ["However,", "we", "believe", "that", "the", "OS", "data", "currently", "available", "is", "not", "sufficiently", "mature", "to", "yield", "any", "definitive", "conclusions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p13_s2", "idA": "908259_14_item1_p21_s0", "sentA": "PNETs are highly vascularized tumors which originate in the pancreas.", "sentB": "The most common site of occurrence of NETs in the US population is in the gastrointestinal tract, with over half the tumors located at this site.", "type": 1, "words": ["<tag1>", "PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas.", "<tag2>", "The", "most", "common", "site", "of", "occurrence", "of", "NETs", "in", "the", "US", "population", "is", "in", "the", "gastrointestinal", "tract,", "with", "over", "half", "the", "tumors", "located", "at", "this", "site.", "<tag3>"], "wordsA": ["PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas."], "wordsB": ["The", "most", "common", "site", "of", "occurrence", "of", "NETs", "in", "the", "US", "population", "is", "in", "the", "gastrointestinal", "tract,", "with", "over", "half", "the", "tumors", "located", "at", "this", "site."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p3_s2", "idA": "908259_14_item1_p2_s1", "sentA": "This form of cancer begins in the ovaries and often spreads to the rest of the pelvis and abdomen prior to detection, resulting in a relatively poor prognosis.", "sentB": "One quarter of those who relapse after initial treatment, or more than 4,300 women, will have platinum-resistant cancer, the most difficult-to-treat form of the disease.", "type": 1, "words": ["<tag1>", "This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis.", "<tag2>", "One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease.", "<tag3>"], "wordsA": ["This", "form", "of", "cancer", "begins", "in", "the", "ovaries", "and", "often", "spreads", "to", "the", "rest", "of", "the", "pelvis", "and", "abdomen", "prior", "to", "detection,", "resulting", "in", "a", "relatively", "poor", "prognosis."], "wordsB": ["One", "quarter", "of", "those", "who", "relapse", "after", "initial", "treatment,", "or", "more", "than", "4,300", "women,", "will", "have", "platinum-resistant", "cancer,", "the", "most", "difficult-to-treat", "form", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p2_s3", "idA": "908259_14_item1_p2_s2", "sentA": "In fact, more than 60% of women diagnosed with ovarian cancer are in stage III or IV, making it difficult to treat and often fatal, with a five-year survival rate of 47% a rate which is largely unchanged since the 1990s.", "sentB": "Overall, approximately 80% of patients diagnosed with ovarian epithelial, fallopian tube, and primary peritoneal cancer will relapse after first-line platinum-based and taxane-based chemotherapy.", "type": 1, "words": ["<tag1>", "In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s.", "<tag2>", "Overall,", "approximately", "80%", "of", "patients", "diagnosed", "with", "ovarian", "epithelial,", "fallopian", "tube,", "and", "primary", "peritoneal", "cancer", "will", "relapse", "after", "first-line", "platinum-based", "and", "taxane-based", "chemotherapy.", "<tag3>"], "wordsA": ["In", "fact,", "more", "than", "60%", "of", "women", "diagnosed", "with", "ovarian", "cancer", "are", "in", "stage", "III", "or", "IV,", "making", "it", "difficult", "to", "treat", "and", "often", "fatal,", "with", "a", "five-year", "survival", "rate", "of", "47%", "a", "rate", "which", "is", "largely", "unchanged", "since", "the", "1990s."], "wordsB": ["Overall,", "approximately", "80%", "of", "patients", "diagnosed", "with", "ovarian", "epithelial,", "fallopian", "tube,", "and", "primary", "peritoneal", "cancer", "will", "relapse", "after", "first-line", "platinum-based", "and", "taxane-based", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p3_s0", "idA": "908259_14_item1_p3_s0", "sentA": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer, including carboplatin and cisplatin, gemcitabine, doxorubicin, and paclitaxel and also in the European Union, bevacizumab.", "sentB": "When treating recurrent ovarian cancer, the time between receiving the last dose of platinum-based chemotherapy and disease recurrence is used to help determine the choice of chemotherapy used in the next line of treatment.", "type": 1, "words": ["<tag1>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab.", "<tag2>", "When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment.", "<tag3>"], "wordsA": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer,", "including", "carboplatin", "and", "cisplatin,", "gemcitabine,", "doxorubicin,", "and", "paclitaxel", "and", "also", "in", "the", "European", "Union,", "bevacizumab."], "wordsB": ["When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s0", "idA": "908259_14_item1_p42_s2", "sentA": "By binding to the tubulin, ZYBRESTAT is able to collapse the structural framework that maintains the cells flat shape.", "sentB": "It is our belief, based on the available preclinical data, that by reducing blood flow to the tumors using fosbretabulin, we may be able to reduce the production of tumor-derived materials, including these biologically active substances.", "type": 1, "words": ["<tag1>", "By", "binding", "to", "the", "tubulin,", "ZYBRESTAT", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape.", "<tag2>", "It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "the", "tumors", "using", "fosbretabulin,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "materials,", "including", "these", "biologically", "active", "substances.", "<tag3>"], "wordsA": ["By", "binding", "to", "the", "tubulin,", "ZYBRESTAT", "is", "able", "to", "collapse", "the", "structural", "framework", "that", "maintains", "the", "cells", "flat", "shape."], "wordsB": ["It", "is", "our", "belief,", "based", "on", "the", "available", "preclinical", "data,", "that", "by", "reducing", "blood", "flow", "to", "the", "tumors", "using", "fosbretabulin,", "we", "may", "be", "able", "to", "reduce", "the", "production", "of", "tumor-derived", "materials,", "including", "these", "biologically", "active", "substances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p3_s3", "idA": "908259_14_item1_p45_s5", "sentA": "Like approved anti-angiogenic drugs, ZYBRESTAT also exhibits cardiovascular effects, which in the majority of patients are mild and transient in nature.", "sentB": "Additionally, a majority of patients who are not initially platinum-resistant and who may achieve a full remission following first-line therapy will also develop recurrent disease.", "type": 1, "words": ["<tag1>", "Like", "approved", "anti-angiogenic", "drugs,", "ZYBRESTAT", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature.", "<tag2>", "Additionally,", "a", "majority", "of", "patients", "who", "are", "not", "initially", "platinum-resistant", "and", "who", "may", "achieve", "a", "full", "remission", "following", "first-line", "therapy", "will", "also", "develop", "recurrent", "disease.", "<tag3>"], "wordsA": ["Like", "approved", "anti-angiogenic", "drugs,", "ZYBRESTAT", "also", "exhibits", "cardiovascular", "effects,", "which", "in", "the", "majority", "of", "patients", "are", "mild", "and", "transient", "in", "nature."], "wordsB": ["Additionally,", "a", "majority", "of", "patients", "who", "are", "not", "initially", "platinum-resistant", "and", "who", "may", "achieve", "a", "full", "remission", "following", "first-line", "therapy", "will", "also", "develop", "recurrent", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p0_s1", "idA": "908259_14_item1_p46_s1", "sentA": "Our principal focus is to advance the clinical development and commercialization of our drug candidates ZYBRESTAT and OXi4503 and to identify new preclinical candidates that are complementary to our VDAs.", "sentB": "We have two clinical stage product candidates that are currently being developed in three potential oncology indications.", "type": 1, "words": ["<tag1>", "Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs.", "<tag2>", "We", "have", "two", "clinical", "stage", "product", "candidates", "that", "are", "currently", "being", "developed", "in", "three", "potential", "oncology", "indications.", "<tag3>"], "wordsA": ["Our", "principal", "focus", "is", "to", "advance", "the", "clinical", "development", "and", "commercialization", "of", "our", "drug", "candidates", "ZYBRESTAT", "and", "OXi4503", "and", "to", "identify", "new", "preclinical", "candidates", "that", "are", "complementary", "to", "our", "VDAs."], "wordsB": ["We", "have", "two", "clinical", "stage", "product", "candidates", "that", "are", "currently", "being", "developed", "in", "three", "potential", "oncology", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p7_s3", "idA": "908259_14_item1_p46_s6", "sentA": "In 2013, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "sentB": "The hazard ratio was 0.685, with a 90% 2-sided confidence interval (CI) of 0.47 ~1.00.", "type": 1, "words": ["<tag1>", "In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "The", "hazard", "ratio", "was", "0.685,", "with", "a", "90%", "2-sided", "confidence", "interval", "(CI)", "of", "0.47", "~1.00.", "<tag3>"], "wordsA": ["In", "2013,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["The", "hazard", "ratio", "was", "0.685,", "with", "a", "90%", "2-sided", "confidence", "interval", "(CI)", "of", "0.47", "~1.00."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p87_s4", "idA": "908259_14_item1_p59_s1", "sentA": "Under the Angiogene license, we have the right to grant sublicenses.", "sentB": "However, given our current priorities and resources, we have decided not to actively pursue such a filing at this time.", "type": 1, "words": ["<tag1>", "Under", "the", "Angiogene", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses.", "<tag2>", "However,", "given", "our", "current", "priorities", "and", "resources,", "we", "have", "decided", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time.", "<tag3>"], "wordsA": ["Under", "the", "Angiogene", "license,", "we", "have", "the", "right", "to", "grant", "sublicenses."], "wordsB": ["However,", "given", "our", "current", "priorities", "and", "resources,", "we", "have", "decided", "not", "to", "actively", "pursue", "such", "a", "filing", "at", "this", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p8_s2", "idA": "908259_14_item1_p73_s3", "sentA": "If an SPA is appropriate, the FDA will base its assessment on the questions posed by the sponsor.", "sentB": "One patient on the combination regimen had a Grade 3 thromboembolic event.", "type": 1, "words": ["<tag1>", "If", "an", "SPA", "is", "appropriate,", "the", "FDA", "will", "base", "its", "assessment", "on", "the", "questions", "posed", "by", "the", "sponsor.", "<tag2>", "One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event.", "<tag3>"], "wordsA": ["If", "an", "SPA", "is", "appropriate,", "the", "FDA", "will", "base", "its", "assessment", "on", "the", "questions", "posed", "by", "the", "sponsor."], "wordsB": ["One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_15_item1_p16_s1", "idA": "908259_14_item1_p94_s1", "sentA": "If we are successful in obtaining an MAA for ZYBRESTAT in the treatment of ATC, we believe that this could lead to similar authorizations in other countries such as Japan, South Korea, China, or Canada (but not in the United States).", "sentB": "Although our initial focus in NETs is on GI-NETs, we believe that if our clinical development in this area is successful, this approach may have utility in other NETs and other hormone-producing tumors.", "type": 1, "words": ["<tag1>", "If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States).", "<tag2>", "Although", "our", "initial", "focus", "in", "NETs", "is", "on", "GI-NETs,", "we", "believe", "that", "if", "our", "clinical", "development", "in", "this", "area", "is", "successful,", "this", "approach", "may", "have", "utility", "in", "other", "NETs", "and", "other", "hormone-producing", "tumors.", "<tag3>"], "wordsA": ["If", "we", "are", "successful", "in", "obtaining", "an", "MAA", "for", "ZYBRESTAT", "in", "the", "treatment", "of", "ATC,", "we", "believe", "that", "this", "could", "lead", "to", "similar", "authorizations", "in", "other", "countries", "such", "as", "Japan,", "South", "Korea,", "China,", "or", "Canada", "(but", "not", "in", "the", "United", "States)."], "wordsB": ["Although", "our", "initial", "focus", "in", "NETs", "is", "on", "GI-NETs,", "we", "believe", "that", "if", "our", "clinical", "development", "in", "this", "area", "is", "successful,", "this", "approach", "may", "have", "utility", "in", "other", "NETs", "and", "other", "hormone-producing", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p101_s2", "idA": "908259_15_item1_p0_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.", "type": 1, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "A", "member", "state", "may", "approve", "a", "specific", "price", "for", "the", "medicinal", "product", "or", "it", "may", "instead", "adopt", "a", "system", "of", "direct", "or", "indirect", "controls", "on", "the", "profitability", "of", "the", "company", "placing", "the", "medicinal", "product", "on", "the", "market.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["A", "member", "state", "may", "approve", "a", "specific", "price", "for", "the", "medicinal", "product", "or", "it", "may", "instead", "adopt", "a", "system", "of", "direct", "or", "indirect", "controls", "on", "the", "profitability", "of", "the", "company", "placing", "the", "medicinal", "product", "on", "the", "market."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p1_s0", "idA": "908259_15_item1_p0_s0", "sentA": "We are a biopharmaceutical company primarily focused on the development of vascular disrupting agents, or VDAs, for the treatment of cancer.", "sentB": "VDAs are in a class of drugs called vascular targeted therapies, or VTTs, which also includes anti-angiogenic agents, or AAs.", "type": 1, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer.", "<tag2>", "VDAs", "are", "in", "a", "class", "of", "drugs", "called", "vascular", "targeted", "therapies,", "or", "VTTs,", "which", "also", "includes", "anti-angiogenic", "agents,", "or", "AAs.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "primarily", "focused", "on", "the", "development", "of", "vascular", "disrupting", "agents,", "or", "VDAs,", "for", "the", "treatment", "of", "cancer."], "wordsB": ["VDAs", "are", "in", "a", "class", "of", "drugs", "called", "vascular", "targeted", "therapies,", "or", "VTTs,", "which", "also", "includes", "anti-angiogenic", "agents,", "or", "AAs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p25_s1", "idA": "908259_15_item1_p0_s5", "sentA": "We are pursuing what we believe to be a cost-efficient, risk-mitigated development strategy.", "sentB": "Glioblastoma Multiforme We are exploring recurrent glioblastoma multiforme, or GBM, as an additional indication for CA4P because:", "type": 1, "words": ["<tag1>", "We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy.", "<tag2>", "Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:", "<tag3>"], "wordsA": ["We", "are", "pursuing", "what", "we", "believe", "to", "be", "a", "cost-efficient,", "risk-mitigated", "development", "strategy."], "wordsB": ["Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p1_s2", "idA": "908259_15_item1_p18_s0", "sentA": "PNETs are highly vascularized tumors which originate in the pancreas.", "sentB": "Genentech s bevacizumab (Avastin ) has the greatest market share in the class, with 2015 estimated sales of approximately $6.7 billion.", "type": 1, "words": ["<tag1>", "PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas.", "<tag2>", "Genentech", "s", "bevacizumab", "(Avastin", ")", "has", "the", "greatest", "market", "share", "in", "the", "class,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion.", "<tag3>"], "wordsA": ["PNETs", "are", "highly", "vascularized", "tumors", "which", "originate", "in", "the", "pancreas."], "wordsB": ["Genentech", "s", "bevacizumab", "(Avastin", ")", "has", "the", "greatest", "market", "share", "in", "the", "class,", "with", "2015", "estimated", "sales", "of", "approximately", "$6.7", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p0_s1", "idA": "908259_15_item1_p1_s0", "sentA": "Fosbretabulin Development Program Fosbretabulin is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in most solid tumors and causes them to swell, obstructing the flow of blood and starving the tumor of vital nutrients including oxygen.", "sentB": "VDAs selectively target the vasculature of cancer tumors and obstruct a tumor s blood supply without disrupting the blood supply to normal tissues.", "type": 1, "words": ["<tag1>", "Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen.", "<tag2>", "VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues.", "<tag3>"], "wordsA": ["Fosbretabulin", "Development", "Program", "Fosbretabulin", "is", "a", "reversible", "tubulin", "binding", "agent", "that", "selectively", "targets", "the", "endothelial", "cells", "that", "make", "up", "the", "blood", "vessel", "walls", "in", "most", "solid", "tumors", "and", "causes", "them", "to", "swell,", "obstructing", "the", "flow", "of", "blood", "and", "starving", "the", "tumor", "of", "vital", "nutrients", "including", "oxygen."], "wordsB": ["VDAs", "selectively", "target", "the", "vasculature", "of", "cancer", "tumors", "and", "obstruct", "a", "tumor", "s", "blood", "supply", "without", "disrupting", "the", "blood", "supply", "to", "normal", "tissues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p29_s0", "idA": "908259_15_item1_p21_s2", "sentA": "Although this pathway continues to remain open to us, our near term priorities for fosbretabulin are focused on our development programs in ovarian cancer and completing our Phase 2 clinical trial in GI-NETs.", "sentB": "Non-Small Cell Lung Carcinoma, or NSCLC We have previously conducted a randomized, controlled clinical trial in NSCLC.", "type": 1, "words": ["<tag1>", "Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs.", "<tag2>", "Non-Small", "Cell", "Lung", "Carcinoma,", "or", "NSCLC", "We", "have", "previously", "conducted", "a", "randomized,", "controlled", "clinical", "trial", "in", "NSCLC.", "<tag3>"], "wordsA": ["Although", "this", "pathway", "continues", "to", "remain", "open", "to", "us,", "our", "near", "term", "priorities", "for", "fosbretabulin", "are", "focused", "on", "our", "development", "programs", "in", "ovarian", "cancer", "and", "completing", "our", "Phase", "2", "clinical", "trial", "in", "GI-NETs."], "wordsB": ["Non-Small", "Cell", "Lung", "Carcinoma,", "or", "NSCLC", "We", "have", "previously", "conducted", "a", "randomized,", "controlled", "clinical", "trial", "in", "NSCLC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s4", "idA": "908259_15_item1_p22_s0", "sentA": "We believe that this dual mechanism differentiates OXi4503 from other VDAs and may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.", "sentB": "We believe that the indirect inhibition on angiogenesis (provided by the AA) combined with the direct effect on established tumor blood vessels (provided by the VDA) would result in a significantly greater benefit to patients than the anti-vascular effect of either drug alone.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates.", "<tag2>", "We", "believe", "that", "the", "indirect", "inhibition", "on", "angiogenesis", "(provided", "by", "the", "AA)", "combined", "with", "the", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "(provided", "by", "the", "VDA)", "would", "result", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "the", "anti-vascular", "effect", "of", "either", "drug", "alone.", "<tag3>"], "wordsA": ["We", "believe", "that", "this", "dual", "mechanism", "differentiates", "OXi4503", "from", "other", "VDAs", "and", "may", "result", "in", "enhanced", "anti-tumor", "activity", "in", "certain", "tumor", "types", "as", "compared", "with", "other", "VDA", "drug", "candidates."], "wordsB": ["We", "believe", "that", "the", "indirect", "inhibition", "on", "angiogenesis", "(provided", "by", "the", "AA)", "combined", "with", "the", "direct", "effect", "on", "established", "tumor", "blood", "vessels", "(provided", "by", "the", "VDA)", "would", "result", "in", "a", "significantly", "greater", "benefit", "to", "patients", "than", "the", "anti-vascular", "effect", "of", "either", "drug", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p19_s1", "idA": "908259_15_item1_p25_s1", "sentA": "This open-label, dose-escalating study was intended to treat up to 36 patients and evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503 in these patients.", "sentB": "In the second stage, we plan to enroll up to 356 additional patients and do not plan to conduct any interim analyses.", "type": 1, "words": ["<tag1>", "This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients.", "<tag2>", "In", "the", "second", "stage,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients", "and", "do", "not", "plan", "to", "conduct", "any", "interim", "analyses.", "<tag3>"], "wordsA": ["This", "open-label,", "dose-escalating", "study", "was", "intended", "to", "treat", "up", "to", "36", "patients", "and", "evaluate", "the", "safety", "profile,", "maximum", "tolerated", "dose", "and", "biologic", "activity", "of", "OXi4503", "in", "these", "patients."], "wordsB": ["In", "the", "second", "stage,", "we", "plan", "to", "enroll", "up", "to", "356", "additional", "patients", "and", "do", "not", "plan", "to", "conduct", "any", "interim", "analyses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p92_s1", "idA": "908259_15_item1_p33_s1", "sentA": "Physician adoption of these first-generation anti-vascular drugs has been rapid and continues to accelerate.", "sentB": "Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue.", "type": 1, "words": ["<tag1>", "Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate.", "<tag2>", "Adoption", "of", "price", "controls", "and", "cost-containment", "measures,", "and", "adoption", "of", "more", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "further", "limit", "our", "net", "revenue.", "<tag3>"], "wordsA": ["Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate."], "wordsB": ["Adoption", "of", "price", "controls", "and", "cost-containment", "measures,", "and", "adoption", "of", "more", "restrictive", "policies", "in", "jurisdictions", "with", "existing", "controls", "and", "measures,", "could", "further", "limit", "our", "net", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p98_s2", "idA": "908259_15_item1_p33_s1", "sentA": "Physician adoption of these first-generation anti-vascular drugs has been rapid and continues to accelerate.", "sentB": "Because of these cost controls, it is hard to determine what impact the ACA s expansion in coverage might have on pharmaceutical companies.", "type": 1, "words": ["<tag1>", "Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate.", "<tag2>", "Because", "of", "these", "cost", "controls,", "it", "is", "hard", "to", "determine", "what", "impact", "the", "ACA", "s", "expansion", "in", "coverage", "might", "have", "on", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["Physician", "adoption", "of", "these", "first-generation", "anti-vascular", "drugs", "has", "been", "rapid", "and", "continues", "to", "accelerate."], "wordsB": ["Because", "of", "these", "cost", "controls,", "it", "is", "hard", "to", "determine", "what", "impact", "the", "ACA", "s", "expansion", "in", "coverage", "might", "have", "on", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p95_s3", "idA": "908259_15_item1_p35_s3", "sentA": "Additionally, positive study results from the Phase 2 GOG-0186I clinical trial indicated a statistically significant increase in PFS with the combination of fosbretabulin and bevacizumab.", "sentB": "Any reduction in payment that results from the MMA or other Medicare regulations may result in a similar reduction in payments from non-governmental payors.", "type": 1, "words": ["<tag1>", "Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab.", "<tag2>", "Any", "reduction", "in", "payment", "that", "results", "from", "the", "MMA", "or", "other", "Medicare", "regulations", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "non-governmental", "payors.", "<tag3>"], "wordsA": ["Additionally,", "positive", "study", "results", "from", "the", "Phase", "2", "GOG-0186I", "clinical", "trial", "indicated", "a", "statistically", "significant", "increase", "in", "PFS", "with", "the", "combination", "of", "fosbretabulin", "and", "bevacizumab."], "wordsB": ["Any", "reduction", "in", "payment", "that", "results", "from", "the", "MMA", "or", "other", "Medicare", "regulations", "may", "result", "in", "a", "similar", "reduction", "in", "payments", "from", "non-governmental", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s2", "idA": "908259_15_item1_p37_s3", "sentA": "When this occurs, the shape of the cells changes from flat to round, initiating a cascade of events resulting in physical blockage of the blood vessels.", "sentB": "When VDAs and AAs are used in combination, our VDAs have been shown to directly cut off the blood supply to the interior of the tumor, while the AA inhibits angiogenesis, which is the process by which new blood vessels form and re-vascularize the tumor.", "type": 1, "words": ["<tag1>", "When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels.", "<tag2>", "When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor.", "<tag3>"], "wordsA": ["When", "this", "occurs,", "the", "shape", "of", "the", "cells", "changes", "from", "flat", "to", "round,", "initiating", "a", "cascade", "of", "events", "resulting", "in", "physical", "blockage", "of", "the", "blood", "vessels."], "wordsB": ["When", "VDAs", "and", "AAs", "are", "used", "in", "combination,", "our", "VDAs", "have", "been", "shown", "to", "directly", "cut", "off", "the", "blood", "supply", "to", "the", "interior", "of", "the", "tumor,", "while", "the", "AA", "inhibits", "angiogenesis,", "which", "is", "the", "process", "by", "which", "new", "blood", "vessels", "form", "and", "re-vascularize", "the", "tumor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p94_s0", "idA": "908259_15_item1_p37_s4", "sentA": "The resulting shutdown in blood-flow then deprives tumor cells of the oxygen and nutrients necessary for maintenance and growth and also prevents tumor cells from being able to excrete toxic metabolic waste products.", "sentB": "Each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level.", "type": 1, "words": ["<tag1>", "The", "resulting", "shutdown", "in", "blood-flow", "then", "deprives", "tumor", "cells", "of", "the", "oxygen", "and", "nutrients", "necessary", "for", "maintenance", "and", "growth", "and", "also", "prevents", "tumor", "cells", "from", "being", "able", "to", "excrete", "toxic", "metabolic", "waste", "products.", "<tag2>", "Each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level.", "<tag3>"], "wordsA": ["The", "resulting", "shutdown", "in", "blood-flow", "then", "deprives", "tumor", "cells", "of", "the", "oxygen", "and", "nutrients", "necessary", "for", "maintenance", "and", "growth", "and", "also", "prevents", "tumor", "cells", "from", "being", "able", "to", "excrete", "toxic", "metabolic", "waste", "products."], "wordsB": ["Each", "drug", "plan", "can", "develop", "its", "own", "drug", "formulary", "that", "identifies", "which", "drugs", "it", "will", "cover", "and", "at", "what", "tier", "or", "level."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p6_s0", "idA": "908259_15_item1_p39_s0", "sentA": "Preclinical and clinical study results indicate that fosbretabulin exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of fosbretabulin in humans is approximately four hours.", "sentB": "Although CA4P acts rapidly, within minutes of infusion, and its circulating half-life is approximately 4 hours, the swelling effect caused by CA4P on the endothelial cells generally lasts for several weeks.", "type": 1, "words": ["<tag1>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours.", "<tag2>", "Although", "CA4P", "acts", "rapidly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "swelling", "effect", "caused", "by", "CA4P", "on", "the", "endothelial", "cells", "generally", "lasts", "for", "several", "weeks.", "<tag3>"], "wordsA": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "fosbretabulin", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "fosbretabulin", "in", "humans", "is", "approximately", "four", "hours."], "wordsB": ["Although", "CA4P", "acts", "rapidly,", "within", "minutes", "of", "infusion,", "and", "its", "circulating", "half-life", "is", "approximately", "4", "hours,", "the", "swelling", "effect", "caused", "by", "CA4P", "on", "the", "endothelial", "cells", "generally", "lasts", "for", "several", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p37_s1", "idA": "908259_15_item1_p41_s6", "sentA": "In 2014, collaborations and agreements were ongoing with a variety of university and research institutions, including the following:", "sentB": "VTTs, which include AAs and VDAs, are designed to interfere with a tumor s vascular supply.", "type": 1, "words": ["<tag1>", "In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:", "<tag2>", "VTTs,", "which", "include", "AAs", "and", "VDAs,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply.", "<tag3>"], "wordsA": ["In", "2014,", "collaborations", "and", "agreements", "were", "ongoing", "with", "a", "variety", "of", "university", "and", "research", "institutions,", "including", "the", "following:"], "wordsB": ["VTTs,", "which", "include", "AAs", "and", "VDAs,", "are", "designed", "to", "interfere", "with", "a", "tumor", "s", "vascular", "supply."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p99_s1", "idA": "908259_15_item1_p49_s15", "sentA": "All licensing fees and milestone payments under the license agreement, in the aggregate amount of $1,080,000, have been paid.", "sentB": "There have been legislative proposals seeking to allow such direct negotiation.", "type": 1, "words": ["<tag1>", "All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "license", "agreement,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid.", "<tag2>", "There", "have", "been", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation.", "<tag3>"], "wordsA": ["All", "licensing", "fees", "and", "milestone", "payments", "under", "the", "license", "agreement,", "in", "the", "aggregate", "amount", "of", "$1,080,000,", "have", "been", "paid."], "wordsB": ["There", "have", "been", "legislative", "proposals", "seeking", "to", "allow", "such", "direct", "negotiation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p101_s1", "idA": "908259_15_item1_p49_s7", "sentA": "We are entitled to file, prosecute and maintain patent applications on products for which we have a license under this agreement.", "sentB": "For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use.", "type": 1, "words": ["<tag1>", "We", "are", "entitled", "to", "file,", "prosecute", "and", "maintain", "patent", "applications", "on", "products", "for", "which", "we", "have", "a", "license", "under", "this", "agreement.", "<tag2>", "For", "example,", "the", "European", "Union", "provides", "options", "for", "its", "member", "states", "to", "restrict", "the", "range", "of", "medicinal", "products", "for", "which", "their", "national", "health", "insurance", "systems", "provide", "reimbursement", "and", "to", "control", "the", "prices", "of", "medicinal", "products", "for", "human", "use.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "file,", "prosecute", "and", "maintain", "patent", "applications", "on", "products", "for", "which", "we", "have", "a", "license", "under", "this", "agreement."], "wordsB": ["For", "example,", "the", "European", "Union", "provides", "options", "for", "its", "member", "states", "to", "restrict", "the", "range", "of", "medicinal", "products", "for", "which", "their", "national", "health", "insurance", "systems", "provide", "reimbursement", "and", "to", "control", "the", "prices", "of", "medicinal", "products", "for", "human", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p2_s3", "idA": "908259_15_item1_p50_s1", "sentA": "Either party may terminate the license upon material default of the other party.", "sentB": "Our current VDA development plans are focused on this combination, in which the mechanism of action of each drug complements that of the other disrupting tumor blood supply in two different ways instead of just one.", "type": 1, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party.", "<tag2>", "Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination,", "in", "which", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "license", "upon", "material", "default", "of", "the", "other", "party."], "wordsB": ["Our", "current", "VDA", "development", "plans", "are", "focused", "on", "this", "combination,", "in", "which", "the", "mechanism", "of", "action", "of", "each", "drug", "complements", "that", "of", "the", "other", "disrupting", "tumor", "blood", "supply", "in", "two", "different", "ways", "instead", "of", "just", "one."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p89_s2", "idA": "908259_15_item1_p60_s5", "sentA": "Each new clinical protocol must be submitted to the IND for FDA review, and to the IRBs for approval.", "sentB": "If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states.", "type": 1, "words": ["<tag1>", "Each", "new", "clinical", "protocol", "must", "be", "submitted", "to", "the", "IND", "for", "FDA", "review,", "and", "to", "the", "IRBs", "for", "approval.", "<tag2>", "If", "a", "member", "state", "does", "not", "recognize", "the", "marketing", "authorization,", "the", "disputed", "points", "are", "eventually", "referred", "to", "the", "European", "Commission,", "whose", "decision", "is", "binding", "on", "all", "member", "states.", "<tag3>"], "wordsA": ["Each", "new", "clinical", "protocol", "must", "be", "submitted", "to", "the", "IND", "for", "FDA", "review,", "and", "to", "the", "IRBs", "for", "approval."], "wordsB": ["If", "a", "member", "state", "does", "not", "recognize", "the", "marketing", "authorization,", "the", "disputed", "points", "are", "eventually", "referred", "to", "the", "European", "Commission,", "whose", "decision", "is", "binding", "on", "all", "member", "states."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p26_s0", "idA": "908259_15_item1_p61_s0", "sentA": "Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:", "sentB": "rapid enrollment would be expected in clinical trials for this indication.", "type": 1, "words": ["<tag1>", "Human", "clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:", "<tag2>", "rapid", "enrollment", "would", "be", "expected", "in", "clinical", "trials", "for", "this", "indication.", "<tag3>"], "wordsA": ["Human", "clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:"], "wordsB": ["rapid", "enrollment", "would", "be", "expected", "in", "clinical", "trials", "for", "this", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s3", "idA": "908259_15_item1_p61_s0", "sentA": "Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:", "sentB": "The ACA also prevents health insurers from charging more, denying, or limiting coverage for individuals with pre-existing conditions (i.e. individuals whose health care costs are typically higher).", "type": 1, "words": ["<tag1>", "Human", "clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:", "<tag2>", "The", "ACA", "also", "prevents", "health", "insurers", "from", "charging", "more,", "denying,", "or", "limiting", "coverage", "for", "individuals", "with", "pre-existing", "conditions", "(i.e.", "individuals", "whose", "health", "care", "costs", "are", "typically", "higher).", "<tag3>"], "wordsA": ["Human", "clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases", "that", "may", "overlap", "or", "be", "combined:"], "wordsB": ["The", "ACA", "also", "prevents", "health", "insurers", "from", "charging", "more,", "denying,", "or", "limiting", "coverage", "for", "individuals", "with", "pre-existing", "conditions", "(i.e.", "individuals", "whose", "health", "care", "costs", "are", "typically", "higher)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s2", "idA": "908259_15_item1_p65_s1", "sentA": "For example, a sponsor may request an SPA of a protocol for a clinical trial that will form the primary basis of an efficacy claim in an NDA.", "sentB": "This clinical trial enrolled chemotherapy-na ve patients, which are patients who have not yet received chemotherapy, which we believe contributed to the high dropout rate among both treatment groups (46.8% and 38.7% for CA4P and control, respectively), making evaluation of progression free survival, the primary endpoint, difficult.", "type": 1, "words": ["<tag1>", "For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA.", "<tag2>", "This", "clinical", "trial", "enrolled", "chemotherapy-na", "ve", "patients,", "which", "are", "patients", "who", "have", "not", "yet", "received", "chemotherapy,", "which", "we", "believe", "contributed", "to", "the", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "progression", "free", "survival,", "the", "primary", "endpoint,", "difficult.", "<tag3>"], "wordsA": ["For", "example,", "a", "sponsor", "may", "request", "an", "SPA", "of", "a", "protocol", "for", "a", "clinical", "trial", "that", "will", "form", "the", "primary", "basis", "of", "an", "efficacy", "claim", "in", "an", "NDA."], "wordsB": ["This", "clinical", "trial", "enrolled", "chemotherapy-na", "ve", "patients,", "which", "are", "patients", "who", "have", "not", "yet", "received", "chemotherapy,", "which", "we", "believe", "contributed", "to", "the", "high", "dropout", "rate", "among", "both", "treatment", "groups", "(46.8%", "and", "38.7%", "for", "CA4P", "and", "control,", "respectively),", "making", "evaluation", "of", "progression", "free", "survival,", "the", "primary", "endpoint,", "difficult."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p89_s1", "idA": "908259_15_item1_p65_s3", "sentA": "After receiving the request, the FDA will consider whether the submission is appropriate for an SPA.", "sentB": "Within 90 days of receiving the applications and assessments report, each member state must decide whether to recognize approval.", "type": 1, "words": ["<tag1>", "After", "receiving", "the", "request,", "the", "FDA", "will", "consider", "whether", "the", "submission", "is", "appropriate", "for", "an", "SPA.", "<tag2>", "Within", "90", "days", "of", "receiving", "the", "applications", "and", "assessments", "report,", "each", "member", "state", "must", "decide", "whether", "to", "recognize", "approval.", "<tag3>"], "wordsA": ["After", "receiving", "the", "request,", "the", "FDA", "will", "consider", "whether", "the", "submission", "is", "appropriate", "for", "an", "SPA."], "wordsB": ["Within", "90", "days", "of", "receiving", "the", "applications", "and", "assessments", "report,", "each", "member", "state", "must", "decide", "whether", "to", "recognize", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s1", "idA": "908259_15_item1_p67_s0", "sentA": "Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA.", "sentB": "The ACA mandated prescription drug coverage as one of ten essential health benefits that most health plans must offer, requiring coverage of at least one drug in every category and class.", "type": 1, "words": ["<tag1>", "Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "trials", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA.", "<tag2>", "The", "ACA", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class.", "<tag3>"], "wordsA": ["Progress", "reports", "detailing", "the", "results", "of", "the", "clinical", "trials", "must", "be", "submitted", "at", "least", "annually", "to", "the", "FDA."], "wordsB": ["The", "ACA", "mandated", "prescription", "drug", "coverage", "as", "one", "of", "ten", "essential", "health", "benefits", "that", "most", "health", "plans", "must", "offer,", "requiring", "coverage", "of", "at", "least", "one", "drug", "in", "every", "category", "and", "class."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p33_s3", "idA": "908259_15_item1_p67_s4", "sentA": "Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB s requirements or if the drug has been associated with unexpected serious harm to patients.", "sentB": "In October 2015, the investigator-sponsored clinical trial was closed, and we brought the clinical trial under our direct management and expanded the number of sites to four, with the goal of enrolling patients faster than had occurred at a single site.", "type": 1, "words": ["<tag1>", "Similarly,", "an", "IRB", "can", "suspend", "or", "terminate", "approval", "of", "a", "clinical", "trial", "at", "its", "institution", "if", "the", "clinical", "trial", "is", "not", "being", "conducted", "in", "accordance", "with", "the", "IRB", "s", "requirements", "or", "if", "the", "drug", "has", "been", "associated", "with", "unexpected", "serious", "harm", "to", "patients.", "<tag2>", "In", "October", "2015,", "the", "investigator-sponsored", "clinical", "trial", "was", "closed,", "and", "we", "brought", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expanded", "the", "number", "of", "sites", "to", "four,", "with", "the", "goal", "of", "enrolling", "patients", "faster", "than", "had", "occurred", "at", "a", "single", "site.", "<tag3>"], "wordsA": ["Similarly,", "an", "IRB", "can", "suspend", "or", "terminate", "approval", "of", "a", "clinical", "trial", "at", "its", "institution", "if", "the", "clinical", "trial", "is", "not", "being", "conducted", "in", "accordance", "with", "the", "IRB", "s", "requirements", "or", "if", "the", "drug", "has", "been", "associated", "with", "unexpected", "serious", "harm", "to", "patients."], "wordsB": ["In", "October", "2015,", "the", "investigator-sponsored", "clinical", "trial", "was", "closed,", "and", "we", "brought", "the", "clinical", "trial", "under", "our", "direct", "management", "and", "expanded", "the", "number", "of", "sites", "to", "four,", "with", "the", "goal", "of", "enrolling", "patients", "faster", "than", "had", "occurred", "at", "a", "single", "site."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p7_s0", "idA": "908259_15_item1_p67_s4", "sentA": "Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB s requirements or if the drug has been associated with unexpected serious harm to patients.", "sentB": "CA4P is given to patients via a 10 minute intravenous infusion.", "type": 1, "words": ["<tag1>", "Similarly,", "an", "IRB", "can", "suspend", "or", "terminate", "approval", "of", "a", "clinical", "trial", "at", "its", "institution", "if", "the", "clinical", "trial", "is", "not", "being", "conducted", "in", "accordance", "with", "the", "IRB", "s", "requirements", "or", "if", "the", "drug", "has", "been", "associated", "with", "unexpected", "serious", "harm", "to", "patients.", "<tag2>", "CA4P", "is", "given", "to", "patients", "via", "a", "10", "minute", "intravenous", "infusion.", "<tag3>"], "wordsA": ["Similarly,", "an", "IRB", "can", "suspend", "or", "terminate", "approval", "of", "a", "clinical", "trial", "at", "its", "institution", "if", "the", "clinical", "trial", "is", "not", "being", "conducted", "in", "accordance", "with", "the", "IRB", "s", "requirements", "or", "if", "the", "drug", "has", "been", "associated", "with", "unexpected", "serious", "harm", "to", "patients."], "wordsB": ["CA4P", "is", "given", "to", "patients", "via", "a", "10", "minute", "intravenous", "infusion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p93_s0", "idA": "908259_15_item1_p77_s2", "sentA": "OXi4503 was awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposes requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries.", "type": 1, "words": ["<tag1>", "OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposes", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries.", "<tag3>"], "wordsA": ["OXi4503", "was", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["The", "Medicare", "Prescription", "Drug,", "Improvement,", "and", "Modernization", "Act", "of", "2003,", "or", "the", "MMA,", "imposes", "requirements", "for", "the", "distribution", "and", "pricing", "of", "prescription", "drugs", "for", "Medicare", "beneficiaries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p98_s1", "idA": "908259_15_item1_p7_s8", "sentA": "Although the subgroup included a relatively small number of patients, these findings suggest that adding fosbretabulin to AVASTIN (bevacizumab) has a potentially greater effect in this difficult-to-treat patient group than for platinum-sensitive patients.", "sentB": "Although the changes have not yet been enacted, the Center for Medicine Services, or CMS, has proposed decreasing the number of categories and classes of drugs Part D plan sponsors must cover.", "type": 1, "words": ["<tag1>", "Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients.", "<tag2>", "Although", "the", "changes", "have", "not", "yet", "been", "enacted,", "the", "Center", "for", "Medicine", "Services,", "or", "CMS,", "has", "proposed", "decreasing", "the", "number", "of", "categories", "and", "classes", "of", "drugs", "Part", "D", "plan", "sponsors", "must", "cover.", "<tag3>"], "wordsA": ["Although", "the", "subgroup", "included", "a", "relatively", "small", "number", "of", "patients,", "these", "findings", "suggest", "that", "adding", "fosbretabulin", "to", "AVASTIN", "(bevacizumab)", "has", "a", "potentially", "greater", "effect", "in", "this", "difficult-to-treat", "patient", "group", "than", "for", "platinum-sensitive", "patients."], "wordsB": ["Although", "the", "changes", "have", "not", "yet", "been", "enacted,", "the", "Center", "for", "Medicine", "Services,", "or", "CMS,", "has", "proposed", "decreasing", "the", "number", "of", "categories", "and", "classes", "of", "drugs", "Part", "D", "plan", "sponsors", "must", "cover."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p97_s0", "idA": "908259_15_item1_p81_s0", "sentA": "Fast Track designation applies to the combination of the product and the specific indication for which it is being studied.", "sentB": "Pharmaceutical manufacturers are required to provide drug rebates to the federal government and most state governments in order to have the product eligible for Medicaid coverage.", "type": 1, "words": ["<tag1>", "Fast", "Track", "designation", "applies", "to", "the", "combination", "of", "the", "product", "and", "the", "specific", "indication", "for", "which", "it", "is", "being", "studied.", "<tag2>", "Pharmaceutical", "manufacturers", "are", "required", "to", "provide", "drug", "rebates", "to", "the", "federal", "government", "and", "most", "state", "governments", "in", "order", "to", "have", "the", "product", "eligible", "for", "Medicaid", "coverage.", "<tag3>"], "wordsA": ["Fast", "Track", "designation", "applies", "to", "the", "combination", "of", "the", "product", "and", "the", "specific", "indication", "for", "which", "it", "is", "being", "studied."], "wordsB": ["Pharmaceutical", "manufacturers", "are", "required", "to", "provide", "drug", "rebates", "to", "the", "federal", "government", "and", "most", "state", "governments", "in", "order", "to", "have", "the", "product", "eligible", "for", "Medicaid", "coverage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p92_s2", "idA": "908259_15_item1_p84_s3", "sentA": "Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product.", "sentB": "If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.", "type": 1, "words": ["<tag1>", "Even", "if", "a", "product", "is", "approved", "by", "a", "regulatory", "authority,", "satisfactory", "prices", "may", "not", "be", "approved", "for", "such", "product.", "<tag2>", "If", "these", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "products", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis.", "<tag3>"], "wordsA": ["Even", "if", "a", "product", "is", "approved", "by", "a", "regulatory", "authority,", "satisfactory", "prices", "may", "not", "be", "approved", "for", "such", "product."], "wordsB": ["If", "these", "third-party", "payors", "do", "not", "consider", "our", "products", "to", "be", "cost-effective", "compared", "to", "other", "available", "therapies,", "they", "may", "not", "cover", "our", "products", "after", "approval", "as", "a", "benefit", "under", "their", "plans", "or,", "if", "they", "do,", "the", "level", "of", "payment", "may", "not", "be", "sufficient", "to", "allow", "us", "to", "sell", "our", "products", "on", "a", "profitable", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p95_s1", "idA": "908259_15_item1_p84_s3", "sentA": "Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product.", "sentB": "However, any negotiated prices for our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain.", "type": 1, "words": ["<tag1>", "Even", "if", "a", "product", "is", "approved", "by", "a", "regulatory", "authority,", "satisfactory", "prices", "may", "not", "be", "approved", "for", "such", "product.", "<tag2>", "However,", "any", "negotiated", "prices", "for", "our", "products", "covered", "by", "a", "Part", "D", "prescription", "drug", "plan", "will", "likely", "be", "lower", "than", "the", "prices", "we", "might", "otherwise", "obtain.", "<tag3>"], "wordsA": ["Even", "if", "a", "product", "is", "approved", "by", "a", "regulatory", "authority,", "satisfactory", "prices", "may", "not", "be", "approved", "for", "such", "product."], "wordsB": ["However,", "any", "negotiated", "prices", "for", "our", "products", "covered", "by", "a", "Part", "D", "prescription", "drug", "plan", "will", "likely", "be", "lower", "than", "the", "prices", "we", "might", "otherwise", "obtain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p88_s2", "idA": "908259_15_item1_p85_s0", "sentA": "In Europe, marketing authorizations may be submitted through a centralized, a decentralized or mutual recognition procedure.", "sentB": "The decentralized procedure provides for mutual recognition of national approval decisions.", "type": 1, "words": ["<tag1>", "In", "Europe,", "marketing", "authorizations", "may", "be", "submitted", "through", "a", "centralized,", "a", "decentralized", "or", "mutual", "recognition", "procedure.", "<tag2>", "The", "decentralized", "procedure", "provides", "for", "mutual", "recognition", "of", "national", "approval", "decisions.", "<tag3>"], "wordsA": ["In", "Europe,", "marketing", "authorizations", "may", "be", "submitted", "through", "a", "centralized,", "a", "decentralized", "or", "mutual", "recognition", "procedure."], "wordsB": ["The", "decentralized", "procedure", "provides", "for", "mutual", "recognition", "of", "national", "approval", "decisions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p88_s0", "idA": "908259_15_item1_p85_s1", "sentA": "The centralized procedure is mandatory for the approval of biotechnology products and provides for the grant of a single marketing authorization that is valid in all European Union members states.", "sentB": "Under European Union regulatory systems, a company may submit marketing authorization applications, or MAAs, either under a centralized or decentralized procedure.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states.", "<tag2>", "Under", "European", "Union", "regulatory", "systems,", "a", "company", "may", "submit", "marketing", "authorization", "applications,", "or", "MAAs,", "either", "under", "a", "centralized", "or", "decentralized", "procedure.", "<tag3>"], "wordsA": ["The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states."], "wordsB": ["Under", "European", "Union", "regulatory", "systems,", "a", "company", "may", "submit", "marketing", "authorization", "applications,", "or", "MAAs,", "either", "under", "a", "centralized", "or", "decentralized", "procedure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p91_s1", "idA": "908259_15_item1_p85_s1", "sentA": "The centralized procedure is mandatory for the approval of biotechnology products and provides for the grant of a single marketing authorization that is valid in all European Union members states.", "sentB": "These third-party payors are increasingly challenging the prices charged for health care products and services.", "type": 1, "words": ["<tag1>", "The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states.", "<tag2>", "These", "third-party", "payors", "are", "increasingly", "challenging", "the", "prices", "charged", "for", "health", "care", "products", "and", "services.", "<tag3>"], "wordsA": ["The", "centralized", "procedure", "is", "mandatory", "for", "the", "approval", "of", "biotechnology", "products", "and", "provides", "for", "the", "grant", "of", "a", "single", "marketing", "authorization", "that", "is", "valid", "in", "all", "European", "Union", "members", "states."], "wordsB": ["These", "third-party", "payors", "are", "increasingly", "challenging", "the", "prices", "charged", "for", "health", "care", "products", "and", "services."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s5", "idA": "908259_15_item1_p86_s1", "sentA": "These pathways are available for drugs to treat serious or debilitating diseases and/or orphan drugs.", "sentB": "For example, the ACA expanded and increased mandatory industry rebates for drugs covered under Medicaid.", "type": 1, "words": ["<tag1>", "These", "pathways", "are", "available", "for", "drugs", "to", "treat", "serious", "or", "debilitating", "diseases", "and/or", "orphan", "drugs.", "<tag2>", "For", "example,", "the", "ACA", "expanded", "and", "increased", "mandatory", "industry", "rebates", "for", "drugs", "covered", "under", "Medicaid.", "<tag3>"], "wordsA": ["These", "pathways", "are", "available", "for", "drugs", "to", "treat", "serious", "or", "debilitating", "diseases", "and/or", "orphan", "drugs."], "wordsB": ["For", "example,", "the", "ACA", "expanded", "and", "increased", "mandatory", "industry", "rebates", "for", "drugs", "covered", "under", "Medicaid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p92_s0", "idA": "908259_15_item1_p87_s8", "sentA": "Our policy is to file U.S. and foreign patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business.", "sentB": "The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products.", "type": 1, "words": ["<tag1>", "Our", "policy", "is", "to", "file", "U.S.", "and", "foreign", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "inventions", "that", "are", "commercially", "important", "to", "the", "development", "of", "our", "business.", "<tag2>", "The", "U.S.", "government,", "state", "legislatures", "and", "foreign", "governments", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "requirements", "for", "substitution", "of", "generic", "products.", "<tag3>"], "wordsA": ["Our", "policy", "is", "to", "file", "U.S.", "and", "foreign", "patent", "applications", "to", "protect", "technology,", "inventions", "and", "improvements", "to", "inventions", "that", "are", "commercially", "important", "to", "the", "development", "of", "our", "business."], "wordsB": ["The", "U.S.", "government,", "state", "legislatures", "and", "foreign", "governments", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "requirements", "for", "substitution", "of", "generic", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p94_s1", "idA": "908259_15_item1_p8_s0", "sentA": "All adverse events in the study were manageable, with one Grade 4 event occurring in each treatment arm.", "sentB": "Federal regulations require Part D prescription drug formularies to include drugs within each therapeutic category and class of covered Part D drugs, although not necessarily all the drugs in each category or class.", "type": 1, "words": ["<tag1>", "All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm.", "<tag2>", "Federal", "regulations", "require", "Part", "D", "prescription", "drug", "formularies", "to", "include", "drugs", "within", "each", "therapeutic", "category", "and", "class", "of", "covered", "Part", "D", "drugs,", "although", "not", "necessarily", "all", "the", "drugs", "in", "each", "category", "or", "class.", "<tag3>"], "wordsA": ["All", "adverse", "events", "in", "the", "study", "were", "manageable,", "with", "one", "Grade", "4", "event", "occurring", "in", "each", "treatment", "arm."], "wordsB": ["Federal", "regulations", "require", "Part", "D", "prescription", "drug", "formularies", "to", "include", "drugs", "within", "each", "therapeutic", "category", "and", "class", "of", "covered", "Part", "D", "drugs,", "although", "not", "necessarily", "all", "the", "drugs", "in", "each", "category", "or", "class."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p39_s2", "idA": "908259_15_item1_p8_s2", "sentA": "One patient on the combination regimen had a Grade 3 thromboembolic event.", "sentB": "AAs, on the other hand, act by preventing the formation of new blood vessels to cancer tumors.", "type": 1, "words": ["<tag1>", "One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event.", "<tag2>", "AAs,", "on", "the", "other", "hand,", "act", "by", "preventing", "the", "formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors.", "<tag3>"], "wordsA": ["One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event."], "wordsB": ["AAs,", "on", "the", "other", "hand,", "act", "by", "preventing", "the", "formation", "of", "new", "blood", "vessels", "to", "cancer", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p96_s0", "idA": "908259_15_item1_p8_s2", "sentA": "One patient on the combination regimen had a Grade 3 thromboembolic event.", "sentB": "The Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010 (collectively, the Affordable Care Act or ACA,) was enacted in March 2010 and has had a significant impact on the health care industry.", "type": 1, "words": ["<tag1>", "One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event.", "<tag2>", "The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "and", "the", "Health", "Care", "and", "Education", "Affordability", "Reconciliation", "Act", "of", "2010", "(collectively,", "the", "Affordable", "Care", "Act", "or", "ACA,)", "was", "enacted", "in", "March", "2010", "and", "has", "had", "a", "significant", "impact", "on", "the", "health", "care", "industry.", "<tag3>"], "wordsA": ["One", "patient", "on", "the", "combination", "regimen", "had", "a", "Grade", "3", "thromboembolic", "event."], "wordsB": ["The", "Patient", "Protection", "and", "Affordable", "Care", "Act", "and", "the", "Health", "Care", "and", "Education", "Affordability", "Reconciliation", "Act", "of", "2010", "(collectively,", "the", "Affordable", "Care", "Act", "or", "ACA,)", "was", "enacted", "in", "March", "2010", "and", "has", "had", "a", "significant", "impact", "on", "the", "health", "care", "industry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p97_s1", "idA": "908259_15_item1_p93_s2", "sentA": "In addition, many of the small companies that compete with us have also formed collaborative relationships with large, established companies to support research, development, clinical trials and commercialization of products that may be competitive with ours.", "sentB": "In addition, commercial insurers offering Medicaid managed care products seek to negotiate additional rebates.", "type": 1, "words": ["<tag1>", "In", "addition,", "many", "of", "the", "small", "companies", "that", "compete", "with", "us", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development,", "clinical", "trials", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours.", "<tag2>", "In", "addition,", "commercial", "insurers", "offering", "Medicaid", "managed", "care", "products", "seek", "to", "negotiate", "additional", "rebates.", "<tag3>"], "wordsA": ["In", "addition,", "many", "of", "the", "small", "companies", "that", "compete", "with", "us", "have", "also", "formed", "collaborative", "relationships", "with", "large,", "established", "companies", "to", "support", "research,", "development,", "clinical", "trials", "and", "commercialization", "of", "products", "that", "may", "be", "competitive", "with", "ours."], "wordsB": ["In", "addition,", "commercial", "insurers", "offering", "Medicaid", "managed", "care", "products", "seek", "to", "negotiate", "additional", "rebates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p95_s2", "idA": "908259_15_item1_p93_s3", "sentA": "Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize products on their own or through joint ventures or other collaborations.", "sentB": "Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.", "type": 1, "words": ["<tag1>", "Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "seeking", "patent", "protection", "and", "may", "commercialize", "products", "on", "their", "own", "or", "through", "joint", "ventures", "or", "other", "collaborations.", "<tag2>", "Moreover,", "while", "the", "MMA", "applies", "only", "to", "drug", "benefits", "for", "Medicare", "beneficiaries,", "private", "payors", "often", "follow", "Medicare", "coverage", "policy", "and", "payment", "limitations", "in", "setting", "their", "own", "payment", "rates.", "<tag3>"], "wordsA": ["Academic", "institutions,", "governmental", "agencies", "and", "other", "public", "and", "private", "research", "organizations", "are", "also", "conducting", "research", "activities", "and", "seeking", "patent", "protection", "and", "may", "commercialize", "products", "on", "their", "own", "or", "through", "joint", "ventures", "or", "other", "collaborations."], "wordsB": ["Moreover,", "while", "the", "MMA", "applies", "only", "to", "drug", "benefits", "for", "Medicare", "beneficiaries,", "private", "payors", "often", "follow", "Medicare", "coverage", "policy", "and", "payment", "limitations", "in", "setting", "their", "own", "payment", "rates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p91_s0", "idA": "908259_15_item1_p94_s2", "sentA": "We expect that, if any of our products gain regulatory approval for sale, they will compete primarily on the basis of product efficacy, safety, patient convenience, reliability, price and patent protection.", "sentB": "Reimbursement Sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations.", "type": 1, "words": ["<tag1>", "We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection.", "<tag2>", "Reimbursement", "Sales", "of", "any", "of", "our", "product", "candidates,", "if", "approved,", "will", "depend,", "in", "part,", "on", "the", "extent", "to", "which", "the", "costs", "of", "the", "products", "will", "be", "covered", "by", "third-party", "payors,", "including", "government", "health", "programs", "such", "as", "Medicare", "and", "Medicaid,", "commercial", "health", "insurers", "and", "managed", "care", "organizations.", "<tag3>"], "wordsA": ["We", "expect", "that,", "if", "any", "of", "our", "products", "gain", "regulatory", "approval", "for", "sale,", "they", "will", "compete", "primarily", "on", "the", "basis", "of", "product", "efficacy,", "safety,", "patient", "convenience,", "reliability,", "price", "and", "patent", "protection."], "wordsB": ["Reimbursement", "Sales", "of", "any", "of", "our", "product", "candidates,", "if", "approved,", "will", "depend,", "in", "part,", "on", "the", "extent", "to", "which", "the", "costs", "of", "the", "products", "will", "be", "covered", "by", "third-party", "payors,", "including", "government", "health", "programs", "such", "as", "Medicare", "and", "Medicaid,", "commercial", "health", "insurers", "and", "managed", "care", "organizations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_16_item1_p30_s0", "idA": "908259_15_item1_p9_s0", "sentA": "All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol.", "sentB": "NSCLC accounts for most cases of lung cancer, and generally does not respond well to chemotherapy.", "type": 1, "words": ["<tag1>", "All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol.", "<tag2>", "NSCLC", "accounts", "for", "most", "cases", "of", "lung", "cancer,", "and", "generally", "does", "not", "respond", "well", "to", "chemotherapy.", "<tag3>"], "wordsA": ["All", "cases", "of", "hypertension", "were", "managed", "with", "antihypertensive", "treatments,", "as", "specified", "in", "the", "study", "protocol."], "wordsB": ["NSCLC", "accounts", "for", "most", "cases", "of", "lung", "cancer,", "and", "generally", "does", "not", "respond", "well", "to", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s6", "idA": "908259_16_item1_p108_s0", "sentA": "COMPETITION The industry in which we are engaged is characterized by rapidly evolving technology and intense competition.", "sentB": "Based on these initial results, we are now planning additional preclinical work in this area.", "type": 1, "words": ["<tag1>", "COMPETITION", "The", "industry", "in", "which", "we", "are", "engaged", "is", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition.", "<tag2>", "Based", "on", "these", "initial", "results,", "we", "are", "now", "planning", "additional", "preclinical", "work", "in", "this", "area.", "<tag3>"], "wordsA": ["COMPETITION", "The", "industry", "in", "which", "we", "are", "engaged", "is", "characterized", "by", "rapidly", "evolving", "technology", "and", "intense", "competition."], "wordsB": ["Based", "on", "these", "initial", "results,", "we", "are", "now", "planning", "additional", "preclinical", "work", "in", "this", "area."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p72_s1", "idA": "908259_16_item1_p109_s6", "sentA": "As of March 23, 2016, we had a total of 15 full-time employees.", "sentB": "In 2016, we changed our name to Mateon Therapeutics, Inc.", "type": 1, "words": ["<tag1>", "As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees.", "<tag2>", "In", "2016,", "we", "changed", "our", "name", "to", "Mateon", "Therapeutics,", "Inc.", "<tag3>"], "wordsA": ["As", "of", "March", "23,", "2016,", "we", "had", "a", "total", "of", "15", "full-time", "employees."], "wordsB": ["In", "2016,", "we", "changed", "our", "name", "to", "Mateon", "Therapeutics,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p33_s1", "idA": "908259_16_item1_p10_s0", "sentA": "There are relatively few cancer therapies that have been approved for the treatment of ovarian cancer including platinum-resistant cancer.", "sentB": "However, these immune oncology agents have significant limitations when used as single agents to treat cancer, since relatively few patients achieve a durable clinical response following treatment.", "type": 1, "words": ["<tag1>", "There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer.", "<tag2>", "However,", "these", "immune", "oncology", "agents", "have", "significant", "limitations", "when", "used", "as", "single", "agents", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment.", "<tag3>"], "wordsA": ["There", "are", "relatively", "few", "cancer", "therapies", "that", "have", "been", "approved", "for", "the", "treatment", "of", "ovarian", "cancer", "including", "platinum-resistant", "cancer."], "wordsB": ["However,", "these", "immune", "oncology", "agents", "have", "significant", "limitations", "when", "used", "as", "single", "agents", "to", "treat", "cancer,", "since", "relatively", "few", "patients", "achieve", "a", "durable", "clinical", "response", "following", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p12_s4", "idA": "908259_16_item1_p13_s2", "sentA": "The results indicated a statistically significant increase in progression-free survival (PFS) in the combination arm, which was the primary endpoint of the trial, with a p-value of 0.049 (pre-specified analysis using a one-sided test; 10% level of significance).", "sentB": "Accordingly, PFS is the primary endpoint for our FOCUS trial.", "type": 1, "words": ["<tag1>", "The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance).", "<tag2>", "Accordingly,", "PFS", "is", "the", "primary", "endpoint", "for", "our", "FOCUS", "trial.", "<tag3>"], "wordsA": ["The", "results", "indicated", "a", "statistically", "significant", "increase", "in", "progression-free", "survival", "(PFS)", "in", "the", "combination", "arm,", "which", "was", "the", "primary", "endpoint", "of", "the", "trial,", "with", "a", "p-value", "of", "0.049", "(pre-specified", "analysis", "using", "a", "one-sided", "test;", "10%", "level", "of", "significance)."], "wordsB": ["Accordingly,", "PFS", "is", "the", "primary", "endpoint", "for", "our", "FOCUS", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p44_s3", "idA": "908259_16_item1_p13_s8", "sentA": "These findings suggest that adding CA4P to bevacizumab has a greater effect in the difficult-to-treat platinum-resistant patient group than it does for platinum-sensitive patients.", "sentB": "The CR in this cohort is particularly encouraging because the patient has a high risk TP53 gene mutation.", "type": 1, "words": ["<tag1>", "These", "findings", "suggest", "that", "adding", "CA4P", "to", "bevacizumab", "has", "a", "greater", "effect", "in", "the", "difficult-to-treat", "platinum-resistant", "patient", "group", "than", "it", "does", "for", "platinum-sensitive", "patients.", "<tag2>", "The", "CR", "in", "this", "cohort", "is", "particularly", "encouraging", "because", "the", "patient", "has", "a", "high", "risk", "TP53", "gene", "mutation.", "<tag3>"], "wordsA": ["These", "findings", "suggest", "that", "adding", "CA4P", "to", "bevacizumab", "has", "a", "greater", "effect", "in", "the", "difficult-to-treat", "platinum-resistant", "patient", "group", "than", "it", "does", "for", "platinum-sensitive", "patients."], "wordsB": ["The", "CR", "in", "this", "cohort", "is", "particularly", "encouraging", "because", "the", "patient", "has", "a", "high", "risk", "TP53", "gene", "mutation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p16_s6", "idA": "908259_16_item1_p14_s1", "sentA": "In the clinical trial, patients with measurable disease who received the combination of CA4P and bevacizumab also achieved a higher objective response rate, or ORR, a secondary endpoint in the clinical trial, measured according to RECIST criteria.", "sentB": "Additional analyses were conducted on patients with measurable disease whose tumors were larger than the median baseline tumor size (tumor size 5.7 cm; n=41), showing CA4P-treated patients with these larger tumors experienced a 48% reduction in the risk of death (HR=0.52; p=0.095) and a 6.2 month improvement in median PFS (10.5 vs. 4.3 months; HR=0.55, p=0.071) compared to control patients.", "type": 1, "words": ["<tag1>", "In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria.", "<tag2>", "Additional", "analyses", "were", "conducted", "on", "patients", "with", "measurable", "disease", "whose", "tumors", "were", "larger", "than", "the", "median", "baseline", "tumor", "size", "(tumor", "size", "5.7", "cm;", "n=41),", "showing", "CA4P-treated", "patients", "with", "these", "larger", "tumors", "experienced", "a", "48%", "reduction", "in", "the", "risk", "of", "death", "(HR=0.52;", "p=0.095)", "and", "a", "6.2", "month", "improvement", "in", "median", "PFS", "(10.5", "vs.", "4.3", "months;", "HR=0.55,", "p=0.071)", "compared", "to", "control", "patients.", "<tag3>"], "wordsA": ["In", "the", "clinical", "trial,", "patients", "with", "measurable", "disease", "who", "received", "the", "combination", "of", "CA4P", "and", "bevacizumab", "also", "achieved", "a", "higher", "objective", "response", "rate,", "or", "ORR,", "a", "secondary", "endpoint", "in", "the", "clinical", "trial,", "measured", "according", "to", "RECIST", "criteria."], "wordsB": ["Additional", "analyses", "were", "conducted", "on", "patients", "with", "measurable", "disease", "whose", "tumors", "were", "larger", "than", "the", "median", "baseline", "tumor", "size", "(tumor", "size", "5.7", "cm;", "n=41),", "showing", "CA4P-treated", "patients", "with", "these", "larger", "tumors", "experienced", "a", "48%", "reduction", "in", "the", "risk", "of", "death", "(HR=0.52;", "p=0.095)", "and", "a", "6.2", "month", "improvement", "in", "median", "PFS", "(10.5", "vs.", "4.3", "months;", "HR=0.55,", "p=0.071)", "compared", "to", "control", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p42_s1", "idA": "908259_16_item1_p17_s1", "sentA": "Bevacizumab is also approved in the EU in combination with different chemotherapy regimens for platinum-resistant and platinum-sensitive ovarian cancer, and the EU approvals were also based on PFS.", "sentB": "The second cohort enrolled 4 patients, each receiving a dose of 4.68 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine.", "type": 1, "words": ["<tag1>", "Bevacizumab", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "and", "the", "EU", "approvals", "were", "also", "based", "on", "PFS.", "<tag2>", "The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine.", "<tag3>"], "wordsA": ["Bevacizumab", "is", "also", "approved", "in", "the", "EU", "in", "combination", "with", "different", "chemotherapy", "regimens", "for", "platinum-resistant", "and", "platinum-sensitive", "ovarian", "cancer,", "and", "the", "EU", "approvals", "were", "also", "based", "on", "PFS."], "wordsB": ["The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p32_s1", "idA": "908259_16_item1_p18_s0", "sentA": "The current standard of care for platinum-resistant ovarian cancer is treatment with bevacizumab and chemotherapy.", "sentB": "The FALCON Study only enrolled patients who had not previously received chemotherapy.", "type": 1, "words": ["<tag1>", "The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy.", "<tag2>", "The", "FALCON", "Study", "only", "enrolled", "patients", "who", "had", "not", "previously", "received", "chemotherapy.", "<tag3>"], "wordsA": ["The", "current", "standard", "of", "care", "for", "platinum-resistant", "ovarian", "cancer", "is", "treatment", "with", "bevacizumab", "and", "chemotherapy."], "wordsB": ["The", "FALCON", "Study", "only", "enrolled", "patients", "who", "had", "not", "previously", "received", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p25_s0", "idA": "908259_16_item1_p19_s8", "sentA": "In October 2014, the first patient was enrolled in a phase 1b/2 trial of pazopanib with and without CA4P in advanced recurrent ovarian cancer.", "sentB": "A total of 7 patients were enrolled in a follow-up trial, of which 5 patients (71%) had stable disease, including one that continued for 14 months.", "type": 1, "words": ["<tag1>", "In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer.", "<tag2>", "A", "total", "of", "7", "patients", "were", "enrolled", "in", "a", "follow-up", "trial,", "of", "which", "5", "patients", "(71%)", "had", "stable", "disease,", "including", "one", "that", "continued", "for", "14", "months.", "<tag3>"], "wordsA": ["In", "October", "2014,", "the", "first", "patient", "was", "enrolled", "in", "a", "phase", "1b/2", "trial", "of", "pazopanib", "with", "and", "without", "CA4P", "in", "advanced", "recurrent", "ovarian", "cancer."], "wordsB": ["A", "total", "of", "7", "patients", "were", "enrolled", "in", "a", "follow-up", "trial,", "of", "which", "5", "patients", "(71%)", "had", "stable", "disease,", "including", "one", "that", "continued", "for", "14", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p42_s2", "idA": "908259_16_item1_p24_s2", "sentA": "We estimate that initial data from the trial will be available by the third quarter of 2016.", "sentB": "Patients enrolled into the trial were treatment-resistant, end-stage AML/MDS patients who had on average four prior therapy failures before entering the study.", "type": 1, "words": ["<tag1>", "We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016.", "<tag2>", "Patients", "enrolled", "into", "the", "trial", "were", "treatment-resistant,", "end-stage", "AML/MDS", "patients", "who", "had", "on", "average", "four", "prior", "therapy", "failures", "before", "entering", "the", "study.", "<tag3>"], "wordsA": ["We", "estimate", "that", "initial", "data", "from", "the", "trial", "will", "be", "available", "by", "the", "third", "quarter", "of", "2016."], "wordsB": ["Patients", "enrolled", "into", "the", "trial", "were", "treatment-resistant,", "end-stage", "AML/MDS", "patients", "who", "had", "on", "average", "four", "prior", "therapy", "failures", "before", "entering", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p126_s0", "idA": "908259_16_item1_p25_s1", "sentA": "Glioblastoma Multiforme We are exploring recurrent glioblastoma multiforme, or GBM, as an additional indication for CA4P because:", "sentB": "If this trial is successful and BeyondSpring s drug is approved, it could constitute competition for CA4P even though the indications are different.", "type": 1, "words": ["<tag1>", "Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:", "<tag2>", "If", "this", "trial", "is", "successful", "and", "BeyondSpring", "s", "drug", "is", "approved,", "it", "could", "constitute", "competition", "for", "CA4P", "even", "though", "the", "indications", "are", "different.", "<tag3>"], "wordsA": ["Glioblastoma", "Multiforme", "We", "are", "exploring", "recurrent", "glioblastoma", "multiforme,", "or", "GBM,", "as", "an", "additional", "indication", "for", "CA4P", "because:"], "wordsB": ["If", "this", "trial", "is", "successful", "and", "BeyondSpring", "s", "drug", "is", "approved,", "it", "could", "constitute", "competition", "for", "CA4P", "even", "though", "the", "indications", "are", "different."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s3", "idA": "908259_16_item1_p30_s1", "sentA": "Results of the FALCON Study, completed in 2011, which enrolled 63 patients and combined CA4P with both bevacizumab and chemotherapy, showed a numerical improvement in overall response rate for the CA4P group (56.3%) compared to the control group (35.5%), although the results were not statistically significant.", "sentB": "Of these studies, the best results were found combining CA4P with an anti-CTLA4 antibody in an EMT-6 mammary tumor model.", "type": 1, "words": ["<tag1>", "Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant.", "<tag2>", "Of", "these", "studies,", "the", "best", "results", "were", "found", "combining", "CA4P", "with", "an", "anti-CTLA4", "antibody", "in", "an", "EMT-6", "mammary", "tumor", "model.", "<tag3>"], "wordsA": ["Results", "of", "the", "FALCON", "Study,", "completed", "in", "2011,", "which", "enrolled", "63", "patients", "and", "combined", "CA4P", "with", "both", "bevacizumab", "and", "chemotherapy,", "showed", "a", "numerical", "improvement", "in", "overall", "response", "rate", "for", "the", "CA4P", "group", "(56.3%)", "compared", "to", "the", "control", "group", "(35.5%),", "although", "the", "results", "were", "not", "statistically", "significant."], "wordsB": ["Of", "these", "studies,", "the", "best", "results", "were", "found", "combining", "CA4P", "with", "an", "anti-CTLA4", "antibody", "in", "an", "EMT-6", "mammary", "tumor", "model."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s0", "idA": "908259_16_item1_p45_s0", "sentA": "Preclinical and clinical study results indicate that CA4P exerts anti-vascular effects rapidly, within hours of administration, and the half-life of the active form of CA4P in humans is approximately four hours.", "sentB": "Because CA4P causes tumor cell necrosis within hours of its administration, we believe it may in turn release into the circulation tumor antigens that enhance the immune system, and consequently enhance the presence and activity of T-cells within tumors.", "type": 1, "words": ["<tag1>", "Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours.", "<tag2>", "Because", "CA4P", "causes", "tumor", "cell", "necrosis", "within", "hours", "of", "its", "administration,", "we", "believe", "it", "may", "in", "turn", "release", "into", "the", "circulation", "tumor", "antigens", "that", "enhance", "the", "immune", "system,", "and", "consequently", "enhance", "the", "presence", "and", "activity", "of", "T-cells", "within", "tumors.", "<tag3>"], "wordsA": ["Preclinical", "and", "clinical", "study", "results", "indicate", "that", "CA4P", "exerts", "anti-vascular", "effects", "rapidly,", "within", "hours", "of", "administration,", "and", "the", "half-life", "of", "the", "active", "form", "of", "CA4P", "in", "humans", "is", "approximately", "four", "hours."], "wordsB": ["Because", "CA4P", "causes", "tumor", "cell", "necrosis", "within", "hours", "of", "its", "administration,", "we", "believe", "it", "may", "in", "turn", "release", "into", "the", "circulation", "tumor", "antigens", "that", "enhance", "the", "immune", "system,", "and", "consequently", "enhance", "the", "presence", "and", "activity", "of", "T-cells", "within", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p44_s0", "idA": "908259_16_item1_p46_s1", "sentA": "This contrasts with AAs, which are typically administered on a chronic basis so as to constantly maintain levels of drug in the body.", "sentB": "One patient in the 3.75 mg/m 2 cohort experienced a dose-limiting toxicity of hypofibrinogenemia, or low levels of fibrinogen in the blood, with no clinical evidence of bleeding, which resolved with treatment.", "type": 1, "words": ["<tag1>", "This", "contrasts", "with", "AAs,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body.", "<tag2>", "One", "patient", "in", "the", "3.75", "mg/m", "2", "cohort", "experienced", "a", "dose-limiting", "toxicity", "of", "hypofibrinogenemia,", "or", "low", "levels", "of", "fibrinogen", "in", "the", "blood,", "with", "no", "clinical", "evidence", "of", "bleeding,", "which", "resolved", "with", "treatment.", "<tag3>"], "wordsA": ["This", "contrasts", "with", "AAs,", "which", "are", "typically", "administered", "on", "a", "chronic", "basis", "so", "as", "to", "constantly", "maintain", "levels", "of", "drug", "in", "the", "body."], "wordsB": ["One", "patient", "in", "the", "3.75", "mg/m", "2", "cohort", "experienced", "a", "dose-limiting", "toxicity", "of", "hypofibrinogenemia,", "or", "low", "levels", "of", "fibrinogen", "in", "the", "blood,", "with", "no", "clinical", "evidence", "of", "bleeding,", "which", "resolved", "with", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p16_s1", "idA": "908259_16_item1_p48_s0", "sentA": "Side-effects associated with CA4P are generally transient and manageable.", "sentB": "Measurable disease is generally defined as primary tumor sizes greater than 1 cm in diameter, while non-measurable tumors are generally identified and monitored by increased serum CA-125 antigen levels, ascites, or other clinical signs of disease.", "type": 1, "words": ["<tag1>", "Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable.", "<tag2>", "Measurable", "disease", "is", "generally", "defined", "as", "primary", "tumor", "sizes", "greater", "than", "1", "cm", "in", "diameter,", "while", "non-measurable", "tumors", "are", "generally", "identified", "and", "monitored", "by", "increased", "serum", "CA-125", "antigen", "levels,", "ascites,", "or", "other", "clinical", "signs", "of", "disease.", "<tag3>"], "wordsA": ["Side-effects", "associated", "with", "CA4P", "are", "generally", "transient", "and", "manageable."], "wordsB": ["Measurable", "disease", "is", "generally", "defined", "as", "primary", "tumor", "sizes", "greater", "than", "1", "cm", "in", "diameter,", "while", "non-measurable", "tumors", "are", "generally", "identified", "and", "monitored", "by", "increased", "serum", "CA-125", "antigen", "levels,", "ascites,", "or", "other", "clinical", "signs", "of", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p43_s2", "idA": "908259_16_item1_p48_s1", "sentA": "The most frequent CA4P side-effects include acute blood pressure increases, infusion-related side effects such as nausea, vomiting, headache and fatigue, and tumor pain, which is consistent with the drug s mechanism-of-action.", "sentB": "The most common drug-related SAEs were anemia (30%), neutropenia (30%), D-dimer increase (20%), thrombocytopenia (20%), and AST increase (20%).", "type": 1, "words": ["<tag1>", "The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action.", "<tag2>", "The", "most", "common", "drug-related", "SAEs", "were", "anemia", "(30%),", "neutropenia", "(30%),", "D-dimer", "increase", "(20%),", "thrombocytopenia", "(20%),", "and", "AST", "increase", "(20%).", "<tag3>"], "wordsA": ["The", "most", "frequent", "CA4P", "side-effects", "include", "acute", "blood", "pressure", "increases,", "infusion-related", "side", "effects", "such", "as", "nausea,", "vomiting,", "headache", "and", "fatigue,", "and", "tumor", "pain,", "which", "is", "consistent", "with", "the", "drug", "s", "mechanism-of-action."], "wordsB": ["The", "most", "common", "drug-related", "SAEs", "were", "anemia", "(30%),", "neutropenia", "(30%),", "D-dimer", "increase", "(20%),", "thrombocytopenia", "(20%),", "and", "AST", "increase", "(20%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p34_s5", "idA": "908259_16_item1_p66_s1", "sentA": "Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies.", "sentB": "Three of four follow-up studies have also indicated that CA4P combined with immune oncology agents can delay tumor growth these studies were conducted in a larger tumor EMT-6 mammary model, a C3H mammary model and a CT26 colon model, providing additional supportive evidence that CA4P may enhance anti-CTLA4 antibody activity, as well as initial evidence that CA4P may enhance anti PD-1 and PD-L1 activity.", "type": 1, "words": ["<tag1>", "Preclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity", "and", "formulation,", "as", "well", "as", "animal", "studies.", "<tag2>", "Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity.", "<tag3>"], "wordsA": ["Preclinical", "tests", "include", "laboratory", "evaluations", "of", "product", "chemistry,", "toxicity", "and", "formulation,", "as", "well", "as", "animal", "studies."], "wordsB": ["Three", "of", "four", "follow-up", "studies", "have", "also", "indicated", "that", "CA4P", "combined", "with", "immune", "oncology", "agents", "can", "delay", "tumor", "growth", "these", "studies", "were", "conducted", "in", "a", "larger", "tumor", "EMT-6", "mammary", "model,", "a", "C3H", "mammary", "model", "and", "a", "CT26", "colon", "model,", "providing", "additional", "supportive", "evidence", "that", "CA4P", "may", "enhance", "anti-CTLA4", "antibody", "activity,", "as", "well", "as", "initial", "evidence", "that", "CA4P", "may", "enhance", "anti", "PD-1", "and", "PD-L1", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p42_s4", "idA": "908259_16_item1_p67_s2", "sentA": "In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.", "sentB": "One of these two patients remains in CR at 9 months following treatment with OXi4503 and the other remained in CR for approximately 6 months before the disease recurred.", "type": 1, "words": ["<tag1>", "In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "trial", "can", "begin.", "<tag2>", "One", "of", "these", "two", "patients", "remains", "in", "CR", "at", "9", "months", "following", "treatment", "with", "OXi4503", "and", "the", "other", "remained", "in", "CR", "for", "approximately", "6", "months", "before", "the", "disease", "recurred.", "<tag3>"], "wordsA": ["In", "such", "a", "case,", "the", "IND", "sponsor", "and", "the", "FDA", "must", "resolve", "any", "outstanding", "concerns", "before", "the", "clinical", "trial", "can", "begin."], "wordsB": ["One", "of", "these", "two", "patients", "remains", "in", "CR", "at", "9", "months", "following", "treatment", "with", "OXi4503", "and", "the", "other", "remained", "in", "CR", "for", "approximately", "6", "months", "before", "the", "disease", "recurred."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p45_s0", "idA": "908259_16_item1_p74_s4", "sentA": "The submission of an NDA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances, which may include orphan drug status and the first NDA application for a company.", "sentB": "Similar to the first two cohorts, OXi4503 was generally well tolerated and adverse events were also similar to the first two cohorts, with no significant adverse events.", "type": 1, "words": ["<tag1>", "The", "submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company.", "<tag2>", "Similar", "to", "the", "first", "two", "cohorts,", "OXi4503", "was", "generally", "well", "tolerated", "and", "adverse", "events", "were", "also", "similar", "to", "the", "first", "two", "cohorts,", "with", "no", "significant", "adverse", "events.", "<tag3>"], "wordsA": ["The", "submission", "of", "an", "NDA", "is", "subject", "to", "the", "payment", "of", "user", "fees;", "a", "waiver", "of", "such", "fees", "may", "be", "obtained", "under", "certain", "limited", "circumstances,", "which", "may", "include", "orphan", "drug", "status", "and", "the", "first", "NDA", "application", "for", "a", "company."], "wordsB": ["Similar", "to", "the", "first", "two", "cohorts,", "OXi4503", "was", "generally", "well", "tolerated", "and", "adverse", "events", "were", "also", "similar", "to", "the", "first", "two", "cohorts,", "with", "no", "significant", "adverse", "events."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p123_s2", "idA": "908259_16_item1_p83_s1", "sentA": "OXi4503 has been awarded orphan drug status by the FDA for the treatment of acute myelogenous leukemia.", "sentB": "Our ability to obtain and maintain the exclusivity for our products and product candidates by virtue of their orphan drug status is an important part of our intellectual property strategy.", "type": 1, "words": ["<tag1>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "Our", "ability", "to", "obtain", "and", "maintain", "the", "exclusivity", "for", "our", "products", "and", "product", "candidates", "by", "virtue", "of", "their", "orphan", "drug", "status", "is", "an", "important", "part", "of", "our", "intellectual", "property", "strategy.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "FDA", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["Our", "ability", "to", "obtain", "and", "maintain", "the", "exclusivity", "for", "our", "products", "and", "product", "candidates", "by", "virtue", "of", "their", "orphan", "drug", "status", "is", "an", "important", "part", "of", "our", "intellectual", "property", "strategy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p114_s0", "idA": "908259_16_item1_p92_s0", "sentA": "The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products.", "sentB": "The U.S. President and certain members of Congress have stated their intent to repeal the ACA and replace it with new laws and regulations.", "type": 1, "words": ["<tag1>", "The", "U.S.", "government,", "state", "legislatures", "and", "foreign", "governments", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "requirements", "for", "substitution", "of", "generic", "products.", "<tag2>", "The", "U.S.", "President", "and", "certain", "members", "of", "Congress", "have", "stated", "their", "intent", "to", "repeal", "the", "ACA", "and", "replace", "it", "with", "new", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["The", "U.S.", "government,", "state", "legislatures", "and", "foreign", "governments", "have", "shown", "significant", "interest", "in", "implementing", "cost-containment", "programs,", "including", "price", "controls,", "restrictions", "on", "reimbursement", "and", "requirements", "for", "substitution", "of", "generic", "products."], "wordsB": ["The", "U.S.", "President", "and", "certain", "members", "of", "Congress", "have", "stated", "their", "intent", "to", "repeal", "the", "ACA", "and", "replace", "it", "with", "new", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_17_item1_p46_s0", "idA": "908259_16_item1_p9_s0", "sentA": "When treating recurrent ovarian cancer, the time between receiving the last dose of platinum-based chemotherapy and disease recurrence is used to help determine the choice of chemotherapy used in the next line of treatment.", "sentB": "There were no dose-limiting toxicities observed in the third cohort, and following a safety review committee recommendation we initiated enrollment in the fourth cohort, at an OXi4503 dose of 7.81 mg/m 2 .", "type": 1, "words": ["<tag1>", "When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment.", "<tag2>", "There", "were", "no", "dose-limiting", "toxicities", "observed", "in", "the", "third", "cohort,", "and", "following", "a", "safety", "review", "committee", "recommendation", "we", "initiated", "enrollment", "in", "the", "fourth", "cohort,", "at", "an", "OXi4503", "dose", "of", "7.81", "mg/m", "2", ".", "<tag3>"], "wordsA": ["When", "treating", "recurrent", "ovarian", "cancer,", "the", "time", "between", "receiving", "the", "last", "dose", "of", "platinum-based", "chemotherapy", "and", "disease", "recurrence", "is", "used", "to", "help", "determine", "the", "choice", "of", "chemotherapy", "used", "in", "the", "next", "line", "of", "treatment."], "wordsB": ["There", "were", "no", "dose-limiting", "toxicities", "observed", "in", "the", "third", "cohort,", "and", "following", "a", "safety", "review", "committee", "recommendation", "we", "initiated", "enrollment", "in", "the", "fourth", "cohort,", "at", "an", "OXi4503", "dose", "of", "7.81", "mg/m", "2", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s0", "idA": "908259_17_item1_p113_s1", "sentA": "Although the changes have not yet been enacted, the Center for Medicine Services, or CMS, has proposed decreasing the number of categories and classes of drugs Part D plan sponsors must cover.", "sentB": "Potential to be used with many therapies: Current AML treatment is highly variable, and many patients receive multiple classes of drugs during the course of their disease.", "type": 1, "words": ["<tag1>", "Although", "the", "changes", "have", "not", "yet", "been", "enacted,", "the", "Center", "for", "Medicine", "Services,", "or", "CMS,", "has", "proposed", "decreasing", "the", "number", "of", "categories", "and", "classes", "of", "drugs", "Part", "D", "plan", "sponsors", "must", "cover.", "<tag2>", "Potential", "to", "be", "used", "with", "many", "therapies:", "Current", "AML", "treatment", "is", "highly", "variable,", "and", "many", "patients", "receive", "multiple", "classes", "of", "drugs", "during", "the", "course", "of", "their", "disease.", "<tag3>"], "wordsA": ["Although", "the", "changes", "have", "not", "yet", "been", "enacted,", "the", "Center", "for", "Medicine", "Services,", "or", "CMS,", "has", "proposed", "decreasing", "the", "number", "of", "categories", "and", "classes", "of", "drugs", "Part", "D", "plan", "sponsors", "must", "cover."], "wordsB": ["Potential", "to", "be", "used", "with", "many", "therapies:", "Current", "AML", "treatment", "is", "highly", "variable,", "and", "many", "patients", "receive", "multiple", "classes", "of", "drugs", "during", "the", "course", "of", "their", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p7_s1", "idA": "908259_17_item1_p16_s4", "sentA": "In the subgroup of platinum-resistant patients, the addition of CA4P to bevacizumab increased ORR to 40.0% (n=10) compared to 12.5% (n=8) for bevacizumab alone.", "sentB": "Additional analyses of changes induced within tumors following combination therapy have shown that CA4P increases tumor-fighting white blood cell counts, T-cells and cytotoxic T-cells compared to immuno-oncology agents alone.", "type": 1, "words": ["<tag1>", "In", "the", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "CA4P", "to", "bevacizumab", "increased", "ORR", "to", "40.0%", "(n=10)", "compared", "to", "12.5%", "(n=8)", "for", "bevacizumab", "alone.", "<tag2>", "Additional", "analyses", "of", "changes", "induced", "within", "tumors", "following", "combination", "therapy", "have", "shown", "that", "CA4P", "increases", "tumor-fighting", "white", "blood", "cell", "counts,", "T-cells", "and", "cytotoxic", "T-cells", "compared", "to", "immuno-oncology", "agents", "alone.", "<tag3>"], "wordsA": ["In", "the", "subgroup", "of", "platinum-resistant", "patients,", "the", "addition", "of", "CA4P", "to", "bevacizumab", "increased", "ORR", "to", "40.0%", "(n=10)", "compared", "to", "12.5%", "(n=8)", "for", "bevacizumab", "alone."], "wordsB": ["Additional", "analyses", "of", "changes", "induced", "within", "tumors", "following", "combination", "therapy", "have", "shown", "that", "CA4P", "increases", "tumor-fighting", "white", "blood", "cell", "counts,", "T-cells", "and", "cytotoxic", "T-cells", "compared", "to", "immuno-oncology", "agents", "alone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p6_s0", "idA": "908259_17_item1_p16_s6", "sentA": "Additional analyses were conducted on patients with measurable disease whose tumors were larger than the median baseline tumor size (tumor size 5.7 cm; n=41), showing CA4P-treated patients with these larger tumors experienced a 48% reduction in the risk of death (HR=0.52; p=0.095) and a 6.2 month improvement in median PFS (10.5 vs. 4.3 months; HR=0.55, p=0.071) compared to control patients.", "sentB": "model using CA4P combined with anti-CTLA4 antibodies demonstrated a 77% reduction in tumor size compared to immuno- oncology agents alone, and an 89% reduction in tumor size compared to control.", "type": 1, "words": ["<tag1>", "Additional", "analyses", "were", "conducted", "on", "patients", "with", "measurable", "disease", "whose", "tumors", "were", "larger", "than", "the", "median", "baseline", "tumor", "size", "(tumor", "size", "5.7", "cm;", "n=41),", "showing", "CA4P-treated", "patients", "with", "these", "larger", "tumors", "experienced", "a", "48%", "reduction", "in", "the", "risk", "of", "death", "(HR=0.52;", "p=0.095)", "and", "a", "6.2", "month", "improvement", "in", "median", "PFS", "(10.5", "vs.", "4.3", "months;", "HR=0.55,", "p=0.071)", "compared", "to", "control", "patients.", "<tag2>", "model", "using", "CA4P", "combined", "with", "anti-CTLA4", "antibodies", "demonstrated", "a", "77%", "reduction", "in", "tumor", "size", "compared", "to", "immuno-", "oncology", "agents", "alone,", "and", "an", "89%", "reduction", "in", "tumor", "size", "compared", "to", "control.", "<tag3>"], "wordsA": ["Additional", "analyses", "were", "conducted", "on", "patients", "with", "measurable", "disease", "whose", "tumors", "were", "larger", "than", "the", "median", "baseline", "tumor", "size", "(tumor", "size", "5.7", "cm;", "n=41),", "showing", "CA4P-treated", "patients", "with", "these", "larger", "tumors", "experienced", "a", "48%", "reduction", "in", "the", "risk", "of", "death", "(HR=0.52;", "p=0.095)", "and", "a", "6.2", "month", "improvement", "in", "median", "PFS", "(10.5", "vs.", "4.3", "months;", "HR=0.55,", "p=0.071)", "compared", "to", "control", "patients."], "wordsB": ["model", "using", "CA4P", "combined", "with", "anti-CTLA4", "antibodies", "demonstrated", "a", "77%", "reduction", "in", "tumor", "size", "compared", "to", "immuno-", "oncology", "agents", "alone,", "and", "an", "89%", "reduction", "in", "tumor", "size", "compared", "to", "control."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s4", "idA": "908259_17_item1_p34_s4", "sentA": "In this study, 7 of 8 mice receiving a combination of CA4P and an anti-CTLA4 antibody experienced complete remission of their tumors, compared to 1 of 8 in the CA4P monotherapy arm and 2 of 8 in the anti-CTLA4 antibody monotherapy arm.", "sentB": "In the most recently completed dose cohort of OX1222, the fifth dose tested in the study, two of four patients experienced complete remissions of their disease after just one cycle of treatment with 9.76 mg/m2 of OXi4503.", "type": 1, "words": ["<tag1>", "In", "this", "study,", "7", "of", "8", "mice", "receiving", "a", "combination", "of", "CA4P", "and", "an", "anti-CTLA4", "antibody", "experienced", "complete", "remission", "of", "their", "tumors,", "compared", "to", "1", "of", "8", "in", "the", "CA4P", "monotherapy", "arm", "and", "2", "of", "8", "in", "the", "anti-CTLA4", "antibody", "monotherapy", "arm.", "<tag2>", "In", "the", "most", "recently", "completed", "dose", "cohort", "of", "OX1222,", "the", "fifth", "dose", "tested", "in", "the", "study,", "two", "of", "four", "patients", "experienced", "complete", "remissions", "of", "their", "disease", "after", "just", "one", "cycle", "of", "treatment", "with", "9.76", "mg/m2", "of", "OXi4503.", "<tag3>"], "wordsA": ["In", "this", "study,", "7", "of", "8", "mice", "receiving", "a", "combination", "of", "CA4P", "and", "an", "anti-CTLA4", "antibody", "experienced", "complete", "remission", "of", "their", "tumors,", "compared", "to", "1", "of", "8", "in", "the", "CA4P", "monotherapy", "arm", "and", "2", "of", "8", "in", "the", "anti-CTLA4", "antibody", "monotherapy", "arm."], "wordsB": ["In", "the", "most", "recently", "completed", "dose", "cohort", "of", "OX1222,", "the", "fifth", "dose", "tested", "in", "the", "study,", "two", "of", "four", "patients", "experienced", "complete", "remissions", "of", "their", "disease", "after", "just", "one", "cycle", "of", "treatment", "with", "9.76", "mg/m2", "of", "OXi4503."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p16_s1", "idA": "908259_17_item1_p35_s0", "sentA": "Based on preclinical data, we believe that OXi4503 may be particularly active in certain cancers, including AML, which have relatively high levels of the enzymes that facilitate the conversion of OXi4503 into a metabolite that directly kills tumor cells.", "sentB": "These patients generally resort to more tolerable but less efficacious therapies.", "type": 1, "words": ["<tag1>", "Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "certain", "cancers,", "including", "AML,", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells.", "<tag2>", "These", "patients", "generally", "resort", "to", "more", "tolerable", "but", "less", "efficacious", "therapies.", "<tag3>"], "wordsA": ["Based", "on", "preclinical", "data,", "we", "believe", "that", "OXi4503", "may", "be", "particularly", "active", "in", "certain", "cancers,", "including", "AML,", "which", "have", "relatively", "high", "levels", "of", "the", "enzymes", "that", "facilitate", "the", "conversion", "of", "OXi4503", "into", "a", "metabolite", "that", "directly", "kills", "tumor", "cells."], "wordsB": ["These", "patients", "generally", "resort", "to", "more", "tolerable", "but", "less", "efficacious", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s5", "idA": "908259_17_item1_p40_s1", "sentA": "Accordingly, OXi4503 appeared to be reasonably well-tolerated based on these results in patients with relapsed and refractory AML and MDS.", "sentB": "In earlier, lower dose cohorts, there were three patients with complete remissions, which occurred following two cycles of treatment, and two additional patients with meaningful AML blast count reductions.", "type": 1, "words": ["<tag1>", "Accordingly,", "OXi4503", "appeared", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS.", "<tag2>", "In", "earlier,", "lower", "dose", "cohorts,", "there", "were", "three", "patients", "with", "complete", "remissions,", "which", "occurred", "following", "two", "cycles", "of", "treatment,", "and", "two", "additional", "patients", "with", "meaningful", "AML", "blast", "count", "reductions.", "<tag3>"], "wordsA": ["Accordingly,", "OXi4503", "appeared", "to", "be", "reasonably", "well-tolerated", "based", "on", "these", "results", "in", "patients", "with", "relapsed", "and", "refractory", "AML", "and", "MDS."], "wordsB": ["In", "earlier,", "lower", "dose", "cohorts,", "there", "were", "three", "patients", "with", "complete", "remissions,", "which", "occurred", "following", "two", "cycles", "of", "treatment,", "and", "two", "additional", "patients", "with", "meaningful", "AML", "blast", "count", "reductions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s6", "idA": "908259_17_item1_p41_s0", "sentA": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "With the lower doses of OXi4503 tested in OX1222, AML blast count reductions were generally observed after the first cycle of treatment, and the complete remissions were observed after two cycles of treatment.", "type": 1, "words": ["<tag1>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "With", "the", "lower", "doses", "of", "OXi4503", "tested", "in", "OX1222,", "AML", "blast", "count", "reductions", "were", "generally", "observed", "after", "the", "first", "cycle", "of", "treatment,", "and", "the", "complete", "remissions", "were", "observed", "after", "two", "cycles", "of", "treatment.", "<tag3>"], "wordsA": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["With", "the", "lower", "doses", "of", "OXi4503", "tested", "in", "OX1222,", "AML", "blast", "count", "reductions", "were", "generally", "observed", "after", "the", "first", "cycle", "of", "treatment,", "and", "the", "complete", "remissions", "were", "observed", "after", "two", "cycles", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s1", "idA": "908259_17_item1_p41_s0", "sentA": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "Among the first four cohorts, we observed three complete remissions after two cycles of treatment (18%) with low doses of OXi4503 (3.75 to 7.81 mg/m2).", "type": 1, "words": ["<tag1>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "Among", "the", "first", "four", "cohorts,", "we", "observed", "three", "complete", "remissions", "after", "two", "cycles", "of", "treatment", "(18%)", "with", "low", "doses", "of", "OXi4503", "(3.75", "to", "7.81", "mg/m2).", "<tag3>"], "wordsA": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["Among", "the", "first", "four", "cohorts,", "we", "observed", "three", "complete", "remissions", "after", "two", "cycles", "of", "treatment", "(18%)", "with", "low", "doses", "of", "OXi4503", "(3.75", "to", "7.81", "mg/m2)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s3", "idA": "908259_17_item1_p41_s0", "sentA": "In December 2015 we initiated the second stage of OX1222, in which ascending doses of OXi4503 are being used in combination with cytarabine, an FDA-approved drug for the treatment of AML.", "sentB": "The protocol for OX1222 provides for giving patients additional higher doses of OXi4503 until an MTD is achieved.", "type": 1, "words": ["<tag1>", "In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML.", "<tag2>", "The", "protocol", "for", "OX1222", "provides", "for", "giving", "patients", "additional", "higher", "doses", "of", "OXi4503", "until", "an", "MTD", "is", "achieved.", "<tag3>"], "wordsA": ["In", "December", "2015", "we", "initiated", "the", "second", "stage", "of", "OX1222,", "in", "which", "ascending", "doses", "of", "OXi4503", "are", "being", "used", "in", "combination", "with", "cytarabine,", "an", "FDA-approved", "drug", "for", "the", "treatment", "of", "AML."], "wordsB": ["The", "protocol", "for", "OX1222", "provides", "for", "giving", "patients", "additional", "higher", "doses", "of", "OXi4503", "until", "an", "MTD", "is", "achieved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p18_s2", "idA": "908259_17_item1_p42_s1", "sentA": "The second cohort enrolled 4 patients, each receiving a dose of 4.68 mg/m 2 of OXi4503 in combination with the same intermediate dose of cytarabine.", "sentB": "In the fifth cohort, we observed two complete remissions after one cycle of treatment (50%) with a higher dose of OXi4503 (9.76 mg/m2), and have not observed dose-limiting toxicities or reached the maximum tolerable dose (MTD).", "type": 1, "words": ["<tag1>", "The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine.", "<tag2>", "In", "the", "fifth", "cohort,", "we", "observed", "two", "complete", "remissions", "after", "one", "cycle", "of", "treatment", "(50%)", "with", "a", "higher", "dose", "of", "OXi4503", "(9.76", "mg/m2),", "and", "have", "not", "observed", "dose-limiting", "toxicities", "or", "reached", "the", "maximum", "tolerable", "dose", "(MTD).", "<tag3>"], "wordsA": ["The", "second", "cohort", "enrolled", "4", "patients,", "each", "receiving", "a", "dose", "of", "4.68", "mg/m", "2", "of", "OXi4503", "in", "combination", "with", "the", "same", "intermediate", "dose", "of", "cytarabine."], "wordsB": ["In", "the", "fifth", "cohort,", "we", "observed", "two", "complete", "remissions", "after", "one", "cycle", "of", "treatment", "(50%)", "with", "a", "higher", "dose", "of", "OXi4503", "(9.76", "mg/m2),", "and", "have", "not", "observed", "dose-limiting", "toxicities", "or", "reached", "the", "maximum", "tolerable", "dose", "(MTD)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p1_s0", "idA": "908259_17_item1_p42_s4", "sentA": "One of these two patients remains in CR at 9 months following treatment with OXi4503 and the other remained in CR for approximately 6 months before the disease recurred.", "sentB": "Using OXi4503 as a treatment for acute myeloid leukemia Both of these programs have potential to generate additional new data before the end of 2018.", "type": 1, "words": ["<tag1>", "One", "of", "these", "two", "patients", "remains", "in", "CR", "at", "9", "months", "following", "treatment", "with", "OXi4503", "and", "the", "other", "remained", "in", "CR", "for", "approximately", "6", "months", "before", "the", "disease", "recurred.", "<tag2>", "Using", "OXi4503", "as", "a", "treatment", "for", "acute", "myeloid", "leukemia", "Both", "of", "these", "programs", "have", "potential", "to", "generate", "additional", "new", "data", "before", "the", "end", "of", "2018.", "<tag3>"], "wordsA": ["One", "of", "these", "two", "patients", "remains", "in", "CR", "at", "9", "months", "following", "treatment", "with", "OXi4503", "and", "the", "other", "remained", "in", "CR", "for", "approximately", "6", "months", "before", "the", "disease", "recurred."], "wordsB": ["Using", "OXi4503", "as", "a", "treatment", "for", "acute", "myeloid", "leukemia", "Both", "of", "these", "programs", "have", "potential", "to", "generate", "additional", "new", "data", "before", "the", "end", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p17_s6", "idA": "908259_17_item1_p61_s0", "sentA": "Our primary focus is on advancing the clinical development of our drug candidates CA4P and OXi4503.", "sentB": "The key elements of our strategy currently include:", "type": 1, "words": ["<tag1>", "Our", "primary", "focus", "is", "on", "advancing", "the", "clinical", "development", "of", "our", "drug", "candidates", "CA4P", "and", "OXi4503.", "<tag2>", "The", "key", "elements", "of", "our", "strategy", "currently", "include:", "<tag3>"], "wordsA": ["Our", "primary", "focus", "is", "on", "advancing", "the", "clinical", "development", "of", "our", "drug", "candidates", "CA4P", "and", "OXi4503."], "wordsB": ["The", "key", "elements", "of", "our", "strategy", "currently", "include:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s2", "idA": "908259_17_item1_p6_s2", "sentA": "Our second compound, OXi4503, is being studied in combination with cytarabine in an ascending-dose phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).", "sentB": "Our most clinically advanced compound, OXi4503, is in development as a potential new treatment for relapsed/refractory AML.", "type": 1, "words": ["<tag1>", "Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS).", "<tag2>", "Our", "most", "clinically", "advanced", "compound,", "OXi4503,", "is", "in", "development", "as", "a", "potential", "new", "treatment", "for", "relapsed/refractory", "AML.", "<tag3>"], "wordsA": ["Our", "second", "compound,", "OXi4503,", "is", "being", "studied", "in", "combination", "with", "cytarabine", "in", "an", "ascending-dose", "phase", "1/2", "clinical", "trial", "in", "patients", "with", "relapsed", "or", "refractory", "acute", "myeloid", "leukemia", "(AML)", "or", "myelodysplastic", "syndromes", "(MDS)."], "wordsB": ["Our", "most", "clinically", "advanced", "compound,", "OXi4503,", "is", "in", "development", "as", "a", "potential", "new", "treatment", "for", "relapsed/refractory", "AML."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p12_s0", "idA": "908259_17_item1_p74_s4", "sentA": "Any agency or judicial enforcement action could have a material adverse effect on us.", "sentB": "Patients with relapsed/refractory AML are most commonly treated with chemotherapy, and generally have a poor prognosis, with a one-year survival of only 29% after their first relapse.", "type": 1, "words": ["<tag1>", "Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us.", "<tag2>", "Patients", "with", "relapsed/refractory", "AML", "are", "most", "commonly", "treated", "with", "chemotherapy,", "and", "generally", "have", "a", "poor", "prognosis,", "with", "a", "one-year", "survival", "of", "only", "29%", "after", "their", "first", "relapse.", "<tag3>"], "wordsA": ["Any", "agency", "or", "judicial", "enforcement", "action", "could", "have", "a", "material", "adverse", "effect", "on", "us."], "wordsB": ["Patients", "with", "relapsed/refractory", "AML", "are", "most", "commonly", "treated", "with", "chemotherapy,", "and", "generally", "have", "a", "poor", "prognosis,", "with", "a", "one-year", "survival", "of", "only", "29%", "after", "their", "first", "relapse."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "908259_18_item1_p14_s0", "idA": "908259_17_item1_p95_s4", "sentA": "OXi4503 has been awarded orphan drug status by the European Commission in the European Union for the treatment of acute myelogenous leukemia.", "sentB": "OXi4503 has been demonstrated in preclinical studies to work in AML by disrupting tumor blood vessels in the bone marrow, forcing otherwise-dormant leukemic stem cells, which are attached to these tumor blood vessels, into circulation in the blood stream as well as into the active cell cycle, where they become vulnerable to chemotherapy.", "type": 1, "words": ["<tag1>", "OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia.", "<tag2>", "OXi4503", "has", "been", "demonstrated", "in", "preclinical", "studies", "to", "work", "in", "AML", "by", "disrupting", "tumor", "blood", "vessels", "in", "the", "bone", "marrow,", "forcing", "otherwise-dormant", "leukemic", "stem", "cells,", "which", "are", "attached", "to", "these", "tumor", "blood", "vessels,", "into", "circulation", "in", "the", "blood", "stream", "as", "well", "as", "into", "the", "active", "cell", "cycle,", "where", "they", "become", "vulnerable", "to", "chemotherapy.", "<tag3>"], "wordsA": ["OXi4503", "has", "been", "awarded", "orphan", "drug", "status", "by", "the", "European", "Commission", "in", "the", "European", "Union", "for", "the", "treatment", "of", "acute", "myelogenous", "leukemia."], "wordsB": ["OXi4503", "has", "been", "demonstrated", "in", "preclinical", "studies", "to", "work", "in", "AML", "by", "disrupting", "tumor", "blood", "vessels", "in", "the", "bone", "marrow,", "forcing", "otherwise-dormant", "leukemic", "stem", "cells,", "which", "are", "attached", "to", "these", "tumor", "blood", "vessels,", "into", "circulation", "in", "the", "blood", "stream", "as", "well", "as", "into", "the", "active", "cell", "cycle,", "where", "they", "become", "vulnerable", "to", "chemotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
